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ABSTRACT: 
 
 This dissertation is devoted to the study of the molecular biology of major tumor 
suppressors, defined as those that prevent the cellular processes identified as the hallmarks of 
cancer.  Specifically, the major tumor suppressors pRb and STK11 are explored in the context of 
osteosarcoma and lung cancer, respectively.  
 RB1 was the first tumor suppressor gene discovered.  Over four decades of work have 
revealed that the Rb protein (pRb) is a master regulator of biological pathways influencing 
virtually every aspect of intrinsic cell fate including cell growth, cell-cycle checkpoints, 
differentiation, senescence, self-renewal, replication, genomic stability and apoptosis.  While 
these many processes may account for a significant portion of RB1’s potency as a tumor 
suppressor, a small, but growing stream of evidence suggests that RB1 also significantly 
influences how a cell interacts with its environment, including cell-to-cell and cell-to-
extracellular matrix interactions.  Chapter 2 highlights pRb’s role in the control of cell adhesion 
and how alterations in the adhesive properties of tumor cells may drive the deadly process of 
metastasis. 
 Chapter 3 defines a role for pRb as a suppressor of the progression to metastasis by 
upregulating integrin α10.  Transcription of this integrin subunit is herein found to be pRb-
dependent in mouse osteoblasts.  Classic pRb partners in cell cycle control, E2F1 and E2F3, do 
not repress transcription of integrin α10 and phosphorylation of pRb is not necessary for 
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activation of the integrin α10 promoter.  Promoter deletion revealed a pRb responsive region 
between -108bp to -55bp upstream of the start of the site of transcription.  pRb activation of 
transcription also leads to increased levels of integrin α10 protein and a greater concentration of 
the integrin α10 protein at the cell membrane of mouse osteoblasts.  These higher levels of 
integrin α10 correspond to increased binding to collagen substrate.  Consistent with our findings 
in mouse osteoblasts, we found that integrin α10 is significantly underexpressed in multiple solid 
tumors that have frequent inactivation of the pRb pathway.  Bioinformatically, we identified data 
consistent with an 'integrin switch' that occurs in multiple solid tumors consisting of 
underexpression of integrins α7, α8, and α10 with concurrent overexpression of integrin β4.  pRb 
promotes cell adhesion by inducing expression of integrins necessary for cell adhesion to a 
substrate. We propose that pRb loss in solid tumors exacerbates aggressiveness by debilitating 
cellular adhesion, which in turn facilitates tumor cell detachment and metastasis. 
 Lung cancer is the leading cause of cancer-related death in the U.S. and additional 
targeted therapies are desperately needed to treat these patients.  STK11 is the third most 
frequently mutated gene in lung adenocarcinoma following only KRAS and TP53, yet its 
mutational status is not currently clinically evaluated and no therapies have been approved to 
specifically target its pathway.  A deep understanding of the complex pathways controlled by 
STK11 and their alterations in cancer are required to develop effective therapies for patients with 
loss-of-function mutations.  In Chapter 4 we present the current understanding of STK11, 
focusing on its molecular biology and therapeutic implications, including a compilation of 
studies evaluating STK11 somatic mutations in human lung cancer tissue and how the frequency 
of these mutations varies across histological subtypes and patient populations.  Finally, we 
review the strategies being used to target STK11-deficient cancers at the clinical trial, pre-
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clinical, and basic science levels as well as proposing potential new therapies that might benefit 
this patient population. 
 STK11 is a tumor-suppressor commonly mutated in lung adenocarcinoma (LuAd).  There 
are a number of agents that may selectively target the deregulated pathways in STK11 mutated 
tumors, and thus, identifying the subset of adenocarcinomas that harbor these mutations could 
have significant clinical benefit.  In Chapter 5, we characterized a cohort of 442 adenocarcinoma 
patients with respect to STK11 mutation status and subset of this cohort using immunochemistry, 
gene expression, and western blotting.  We found that measuring STK11 mutation status is 
complicated by the fact that many STK11 mutations lead to expression of a stable protein that is 
indistinguishable from wild type (WT) via immunohistochemistry.  To circumvent this, we used 
published cell line mutation and gene expression data to derive a signature correlating with 
STK11 mutation status.  This signature was validated in the cohort of 442 lung adenocarcinomas 
and strongly correlates with mutation status (ROC curve AUC = 85.29).  These data suggest that 
STK11 mutation status may be best assessed by measuring the downstream targets included in 
our signature. 
.
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CHAPTER ONE: 
Introduction to Major Tumor Suppressors 
 
MAJOR TUMOR SUPPRESSORS AND THE HALLMARKS OF CANCER 
 
 Cancer is caused by catastrophic failure of numerous cellular processes.  The progression 
from normal cell to cancer cell is a multi-step process involving functional alterations in a series 
of key regulatory proteins which can occur due to genetic mutations, alterations in gene 
expression or due to the activity of infectious agents (e.g., human papilloma virus).  Genes that 
encode proteins that activate cell proliferation are often up-regulated in cancer via over-
expression or by mutations that cause the resulting protein to be constitutively active.  These 
cancer promoting genes are called oncogenes.  Their negative regulatory counterparts, genes that 
encode proteins that prevent cancer from forming, are called tumor suppressors.  Cancers grow 
unchecked once these tumor suppressors are lost by mutation, hyper-phosphorylation, or 
promoter methylation. 
 There have been more than 70 tumor suppressors identified to date
1
 of varying 
importance.  Some are lost late in tumorigenesis and are considered to be 'passenger mutations,' 
those that confer little or no survival advantage to an existing cancer.  Other tumor suppressors 
are lost at the incipient stages of tumor neogenesis, this loss being crucial for the evolution from 
normal cell to cancer cell.  These 'driver mutations' occur in tumor suppressors that act as 
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sentinels, each protecting the integrity of cellular processes crucial to maintaining a normally 
functioning cell. These are the major tumor suppressors. 
 The processes that must occur in order for cancer to develop have been defined as a set of 
eight 'hallmarks of cancer.'  These processes include: sustaining proliferative signaling, evading 
growth suppressors, activating invasion and metastasis, enable replicative immortality, inducing 
angiogenesis, resisting cell death, and the two newest hallmarks: reprogramming energy 
metabolism, and evading immune destruction.
2
  Each of these processes is protected by one or 
more major tumor suppressors as outlined below. 
 'Sustaining proliferative signaling' is quintessentially what makes cancer such a deadly 
disease.  All of the other hallmarks support this unrestricted cellular proliferation in some way.  
While this is a hallmark generally driven by oncogenes, a tumor suppressor that acts as a 
guardian against uncontrolled growth is the phosphatase and tensin homolog (PTEN).  PTEN 
acts as a negative regulator of the AKT pathway serving to dephosphorylate PIP3 into PIP2, 
thereby repressing AKT, signaling to the cell to stop dividing.  Befitting of its status as a major 
tumor suppressor, PTEN is also involved in regulation of apoptosis, migration, adhesion, and 
genetic stability.  It is commonly lost in many human cancers including 30-70% of prostate 
cancer.
3,4
 
 'Evading growth suppressors' is driven by the loss of anti-proliferative signals.  This is a 
process guarded by the first tumor suppressor ever identified, pRb.  pRb serves as a regulator of 
the G1/S transition of cell cycle acting as a transcriptional repressor by binding E2F family 
members at the promoter site of E2F-regulated genes.  Mitogenic signaling activates the 
formation of Cyclin D / CDK4/6 complexes which phosphorylate, and thus inactivate, pRb 
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allowing for cell cycle progression.  pRb has also been linked to numerous other cellular 
processes and is lost or inactivated in the majority of human cancers. 
 'Activating invasion and metastasis' is the multi-step process by which epithelial cells 
acquire the ability to invade adjacent tissues and eventually disseminate to distal sites setting up 
distant metastases.  This process begins with a series of steps known as the epithelial-to-
mesenchymal transition (EMT), controlled by the next major tumor suppressor, transforming 
growth factor β (TGFβ).  TGFβ acts as a tumor suppressor in the early stages of tumorigenesis, 
serving to maintain a favorable cytokine and chemokine profile in the tumor microenvironment.
5-
7
  However, as the disease progresses, oncogenes can serve to convert TGFβ function to induce 
EMT leading to increased invasion and migration.  As such, TGFβ acts as both a major tumor 
suppressor, and at advanced stages of disease, an oncogene. 
 'Enabling replicative immortality' occurs when cells are no longer limited to a finite 
number of cell division cycles.  In healthy cells, the progressive shortening of telomere repeat 
sequences with each subsequent cell division causes cells to lose the ability to protect the ends of 
the chromosomal DNA from forming end-to-end fusions.  The sentinel of genomic integrity is 
p53, which serves to assess DNA damage and activate DNA repair pathways as necessary, or if 
the damage is beyond repair, induce apoptosis.  TP53, which encodes for the p53 protein, is the 
most frequently mutated gene in human tumors with over 25,000 mutations reported to date
I
. 
 'Inducing angiogenesis' is the process by which tumors stimulate the growth of new blood 
vessel vasculature in order to meet the increased metabolic demands of tumor tissues.  The major 
tumor suppressor that prevents this from happening is thrombospondin-1 (TSP-1).  This inhibitor 
of angiogenesis serves to limit vessel density by inhibiting chemotaxis toward pro-angiogenic 
signals and  inducing receptor-mediated apoptosis in activated endothelial cells.
8
  It does this by 
                                                             
I International Agency for Research on Cancer TP53 Database; p53.iarc.fr 
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binding transmembrane receptors displayed by endothelial cells and evoking suppressive signals 
that counteract the proangiogenic stimuli.
9
  
 'Resisting cell death' allows cancer cells to evade all of the aforementioned processes 
whereby tumor suppressors activate apoptosis.  Bax, Bak, and Bok are some of the pro-apoptotic 
proteins responsible for triggering cell death through disrupting the mitochondrial membrane 
resulting in release of cytochrome C.  Apoptosis is a process activated and controlled by many of 
the major tumor suppressors.  Bax and Bak are transcriptional targets of p53, and Bok is 
controlled by E2F, a member of the pRb pathway, in addition to acting as tumor suppressors in 
their own right.  These pro-apoptotic proteins are also suppressed in cancer when outnumbered 
by the anti-apoptotic members of the Bcl-2 family (e.g., Mcl1) which directly bind and inactivate 
their pro-apoptotic counterparts resulting in immortal cancer cells.  Several studies have 
measured these anti- and pro-apoptotic genes across a variety of cancers and found Bok to be 
consistently deleted and Mcl1 to be amplified.
10
 
 'Reprogramming energy metabolism' involves the counterintuitive switch in cancer cells 
from oxidative phosphorylation to glycolysis even in the presence of oxygen.  This phenomenon, 
called the "Warburg effect," causes cancer cells to compensate for the reduced ATP production 
of glycolysis in order to fuel their unrestricted growth.  The major tumor suppressor that serves 
to prevent dysregulated cellular energetics is STK11.  It accomplishes this by suppressing cell 
growth, angiogenesis, and bioenergetics under conditions of nutrient or oxygen stress
11
 through 
its downstream effectors AMPK and mTOR. This is one of the two 'emerging hallmarks' and as 
such, STK11 is one of the least characterized major tumor suppressors. 
 'Evading immune destruction' is the final hallmark and the second of the 'emerging 
hallmarks.'  It can be argued that the entire immune system acts as one of the body's most effect 
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tumor suppressors serving to seek and destroy incipient neoplasias before they ever fully 
develop.  Constant immune surveillance routinely eliminates the vast majority of nascent tumors 
that are highly immunogenic leaving behind weakly immunogenic clones to grow out and 
develop into tumors.  Evading detection by the immune system involves the immunosuppressive 
branches of the immune system including regulatory T cells and myeloid-derived suppressor 
cells and efforts to restore the immune response using cytokines, vaccines and antibody 
immunotherapies (e.g., anti-CTLA4, anti-PD-1) have shown promise in certain patient subsets.
12
   
 The remainder of this dissertation will focus on the major tumor suppressors pRb and 
STK11 in the context of osteosarcoma and lung cancer, respectively. 
 
OSTEOSARCOMA 
 
 Osteosarcoma is a type of cancer that develops in bone tissue.  It primarily affects 
children and young adults, likely linked to ages of rapid bone growth, but risk rises again in 
adults over the age of 60, and is a disease that can occur at any age.  There are thirteen types of 
osteosarcoma that are divided into high-, intermediate-, and low-grade subtypes of varying 
frequencies.  When diagnosed at a localized stage, the 5-year survival rate is 60-80%
II
.  
However, this drops to a survival rate of 15-30% when diagnosed with detectable metastases, 
increasing to approximately 40% if the metastases are exclusively in the lungs or if the tumor, 
including metastases, is completely resectable
II
.  Osteosarcoma is more common in males than 
females and slightly more common in African Americans than in whites.  Children who have 
hereditary retinoblastoma, marked by loss of the major tumor suppressor pRb, have an increased 
risk of osteosarcoma later in life as it is also marked by a high frequency of pRb loss.  Similarly, 
                                                             
II www.cancer.org 
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patients with Li-Fraumeni syndrome, characterized by the loss of the major tumor suppressor 
p53, are also at an increased risk of developing osteosarcoma.  Currently, the options to treat 
osteosarcoma include surgery, chemotherapy, and in certain cases, radiation.  First-line 
chemotherapies include cisplatin, doxorubicin, high-dose methotrexate, ifosfamide, epirubicin, 
or some combination of the above while second-line therapies for refractory or metastatic disease 
include docetaxel, gemcitabine, cyclophosphamide, etoposide, topotecan, sorafenib, or some 
combination thereof
III
.  Luckily, osteosarcoma is a relatively rare disease with only 5.5 boys and 
4.5 girls out of every 1,000,000 aged 0-19 diagnosed in the U.S. between 2006-2010
IV
.  
Unfortunately, this rarity also works against the patients with the disease as research funds are 
channeled to more common diseases.  It is our hope that our work in osteosarcoma will help lead 
to more targeted and effective treatments in the future. 
 
LUNG CANCER 
 
 In contrast to osteosarcoma, lung cancer is the second most diagnosed cancer in both men 
and women following only prostate cancer and breast cancer, respectively and is the leading 
cause of cancer-related death among both men and women, but similar to osteosarcoma, this 
disease also suffers from a dearth of research funds.  It is a disease inextricably linked to 
smoking with risk increasing due to both quantity and duration of smoking.  This perception of 
lung cancer as a lifestyle disease has negatively impacted the research funds being directed 
toward finding a cure for this deadly disease and ignores many of the other causes including 
exposure to asbestos, radon, pollution, second-hand smoke, as well as other occupational 
                                                             
III National Comprehensive Cancer Network; www.nccn.org 
 
IV www.cancer.org 
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hazards.  Our work is focused on understanding the most predominant subtype, non-small cell 
lung cancer (NSCLC) in order to provide benefit to the greatest number of people.  NSCLC 
accounts for approximately 85% of lung cancer diagnoses, with the remainder classified as small 
cell lung cancer.  NSCLC is further subdivided into histological subtypes: adenocarcinoma, 
which accounts for approximately 35-40% all lung cancers, squamous cell carcinoma, which 
accounts for 25-30% of all lung cancers, and large cell carcinoma which accounts 10-15% of all 
lung cancers
V
.  Most lung cancers are diagnosed in patients between 50-70 years old and is 
slightly higher in males compared to females, and slightly higher in African-American men 
compared to white men.  The estimated 5-year survival for lung cancers diagnosed at a local 
stage is 54%, however only 15% of lung cancers fall into this category.  For all stages at 
diagnosis combined, the 5-year survival rate is only 17%
VI
.  Treatment decisions for lung cancer 
have traditionally been based on histological subtype and stage of disease, however more 
recently with the advent of targeted therapies, treatment decisions are being made based on a 
patient's individual spectrum of mutations.  One of the most common mutations in lung 
adenocarcinoma is in the major tumor suppressor, STK11 and this relationship will be discussed 
in detail later in the dissertation. 
 
OVERVIEW OF THE DISSERTATION 
 
 In the following chapters I will describe my work on two major tumor suppressors: pRb 
and STK11.   Chapter 2 describes emerging work linking the tumor suppressor pRb to control 
of cell adhesion and how alterations in this pathway may drive the process of metastasis.  
                                                             
V emedicine.medscape.com 
 
VI www.cancer.org 
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Chapter 3 presents the novel finding that the adhesion protein, integrin α10 is transcriptionally 
activated by the tumor suppressor pRb using osteoblasts as a model system.  It further elucidates 
a signature consisting of changes in expression of four integrin subunits that occurs across 
multiple solid tumor types.  Chapter 4 presents an overview of what is known about the STK11 
tumor suppressor, specifically focusing on its molecular biology and strategies to therapeutically 
target STK11-deficient tumors.  Chapter 5 describes a novel gene expression signature that can 
be used to determine the mutational status of STK11 in lung adenocarcinoma patients and 
clarifies why we believe this is the best option for a clinical diagnostic test.  My conclusions and 
future directions for research are outlined in Chapter 6, as well as describing the current 
methods being explored to restore tumor suppressor function and my thoughts on the future of 
cancer treatment. 
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CHAPTER TWO: 
The Retinoblastoma Protein: A Master Tumor Suppressor Acts as a Link Between Cell 
Cycle and Cell Adhesion
VII
 
 
ABSTRACT 
 
 RB1 was the first tumor suppressor gene discovered.  Over four decades of work have 
revealed that the Rb protein (pRb) is a master regulator of biological pathways influencing 
virtually every aspect of intrinsic cell fate including cell growth, cell-cycle checkpoints, 
differentiation, senescence, self-renewal, replication, genomic stability and apoptosis.  While 
these many processes may account for a significant portion of RB1’s potency as a tumor 
suppressor, a small, but growing stream of evidence suggests that RB1 also significantly 
influences how a cell interacts with its environment, including cell-to-cell and cell-to-
extracellular matrix interactions.  This review will highlight pRb’s role in the control of cell 
adhesion and how alterations in the adhesive properties of tumor cells may drive the deadly 
process of metastasis. 
 
 
 
 
                                                             
VII This chapter will be submitted for publication.  See Appendix A for details. 
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THE RETINOBLASTOMA PROTEIN (pRb): THE CLASSIC PARADIGM 
 
 Existence of the RB1 gene was predicted in 1971 from epidemiological evidence from 
retinoblastoma families
1
 and the RB1 gene was identified over 15 years later.
2
  The initial 
characterization of pRb function was guided by studies of DNA tumor viruses
3,4
 which pointed 
to pRb's role as a regulator of the G1/S transition.
5
  It is now known that both the G1/S and G2/M 
phases of the mammalian cell cycle are controlled by a complex and redundant molecular 
pathway that involves members of the E2 promoter binding factor (E2F)
6
, dimerization partner 
(DP)
7
, pRb
3
, cyclin-dependent kinase (CDKs), Cyclins
8
, and CDK inhibitor(CDKN)
9
 families.  
This pathway is disrupted in most, if not all, solid tumors.
10
 
 While initial work on the function of pRb in cell cycle highlighted its role in the G1/S 
transition, work over the last three decades demonstrates that pRb controls most cellular 
processes related to cell fate and DNA metabolism including cell-cycle checkpoints, tissue 
differentiation and morphogenesis, senescence, self-renewal, replication, tissue-specific gene 
expression, mitotic fidelity, genomic stability and apoptosis.
11-16
.  In this review we will refer to 
these various cell intrinsic processes collectively as cell cycle.  There are a number of 
outstanding articles
17-21
 that review pRb’s role in the cell cycle processes and they will not be 
repeated in detail here. 
 pRb’s activity is regulated by post-translational modifications, phosphorylation being the 
most predominant.
22
  pRb phosphorylation by CDK4-Cyclin D and CDK2-Cyclin E induces S-
phase entry.
23,24
  pRb is phosphorylated on at least 13 different serine/threonine residues 
suggesting that specific patterns of pRb phosphorylation may represent a 'pRb code' in which 
different pRb conformational variants mediate distinct protein-protein interactions.  In non-
12 
 
cancerous cells, anti-proliferative signals activate pRb by promoting its dephosphorylation by 
serine and threonine type I phosphoprotein phosphatases and by inhibiting the Cyclin-CDK 
complexes that phosphorylate pRb.
25-27
  This activation allows pRb to block progression to S-
phase, promoting entry to G0 instead.  A recent review has addressed the complexity of these 
pRb kinases.
22
 
 pRb's strong tumor suppressive nature is evident in the fact that pRb function is lost in 
most human cancers
26,28,29
, and also by the fact that oncogenic insults, such as Ras activation, 
trigger a strong anti-oncogenic senescence program that depends on pRb.
11,30
   Every component 
of the pRb pathway that represses cell cycle is subject to mutational inactivation in some human 
cancers and every component that induces cell cycle is subject to oncogenic up-regulation, 
providing genetic evidence that the pathway as a whole is essential in tumor development. 
CDKN proteins are subjected to inactivating mutations and epigenetic silencing. Cyclins, CDKs, 
and rarely, E2Fs themselves are upregulated by translocations and gene amplifications.
31-34
  The 
rate of RB1 gene mutation varies significantly among different tumor types, but is highest in 
retinoblastoma, osteosarcoma, and small cell lung cancer (SCLC).
28,35
  Mutations targeting the 
RB1 gene directly affect pRb function by either completely abrogating its expression or by 
producing a non-functional protein.
36
  Other cancer types bearing wild type RB1 alleles still have 
impaired pRb function due to alterations in genes coding for upstream pRb regulators.  These 
alterations range from inactivating mutations, deletions or epigenetic silencing of the p16
INK4A
 
locus (a CDKN family member), to alterations leading to Cyclin D or CDK4 overexpression.
32
  
The latter scenario results in pRb inactivation by chronic hyperphosphorylation.  Therefore, 
oncogenesis usually entails either a complete loss of pRb expression or its inactivation by 
hyperphosphorylation. 
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DEREGULATION OF ADHESION PROTEINS IN CANCER 
 
 Cadherins are calcium-dependent cell adhesion proteins that mediate cell-to-cell 
adhesion.  They are named for the tissue that they were first identified in (eg, E-cadherin, N-
cadherin, and OB-cadherin were discovered in epithelial, neural, and osteoblast tissues, 
respectively), but are not restricted exclusively to those tissues.   Cadherins, together with 
catenins, are the main components of adherens junctions, which are membrane protein 
complexes that are stabilized by association with actin filaments densely packed under the cell 
membrane.
37
  Their disruption is part of EMT during oncogenic progression and contributes to 
metastasis by facilitating detachment of cancer cells from the primary tumor.
38
  This disruption 
consists of a 'cadherin switch' whereby expression of E-cadherin is repressed and N-cadherin is 
upregulated.   
 Alterations in integrin expression have also been noted in cancers.  Similar to the 
'cadherin switch' occurring during EMT, an 'integrin switch' has been observed in multiple solid 
tumors consisting of overexpression of integrin β4, and underexpression of integrins α7, α8, and 
α10.39 Integrins are a family of 26 cell-to-extracellular matrix (ECM) adhesion receptor subunits.  
Each functional integrin heterodimer consists of two type-1 (single membrane-spanning domain 
with the C-terminus located cytoplasmically) transmembrane subunits, one α- and one β-subunit.  
Integrins bind to multi-adhesive ECM components, organizing the cytoskeleton and activating 
intracellular signaling pathways.  They have been shown to affect cell shape, polarization, 
cytoskeletal organization, cell motility, proliferation, survival, and differentiation.  Integrins are 
unusual among transmembrane receptors in that they signal bidirectionally, carrying both 
mechanical and chemical signals.  "Inside-out" signaling, known as "priming," is responsible for 
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a conformational change in the integrin heterodimer which extends outward and induces 
adhesiveness to the ECM.  Adhesion is further strengthened by the lateral reorganization of 
integrins into clusters, which may progress to dot-like focal complexes that mature into larger 
focal adhesions and finally into streak-like fibrillar adhesions.
40
  The "integrin adhesome" is 
comprised of 156 signaling, structural, and adaptor molecules that contribute to cytoskeletal 
reorganization and catalytic activity as integrin tails have no catalytic activity of their own.
40
  
Integrin signaling, and the associated cross-talk with adjacent receptor tyrosine kinases, has been 
linked to many pathways important in human cancer including the Ras/Raf/MEK/MAPK, PI3K/ 
PIP3/AKT, NF-κB, and pRb/E2F pathways. 
 
NEW ROLES FOR pRb IN CELL ADHESION: REGULATION OF CADHERIN- AND 
INTEGRIN-MEDIATED ADHESION 
 
 Cancer types showing high frequencies of mutational inactivation of the RB1 gene are 
very aggressive relative to tumors with chronically hyperphosphorylated wild-type pRb.  An 
example is osteosarcoma, which at the time of diagnosis is consistently high grade and poorly 
differentiated.  These patients have a poor prognosis with 20%
VIII
 of diagnosed cases already 
having detectable metastases
41
 and  only  10% achieving long-term disease free intervals.
42
  
Osteosarcoma incidence is increased 1000 fold in patients who inherit RB1 mutations relative to 
the general population,
43
 implicating pRb loss in osteosarcoma formation.  pRb loss occurs in 
over 70% of sporadic osteosarcomas, and loss of RB1 heterozygosity is present in 60-70% of 
osteosarcomas and is indicative of a poor prognosis.
44
 
                                                             
VIII http://www.cancer.org/ 
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 Like osteosarcoma, SCLC is characterized by a high rate (~90%) of mutational 
inactivation of the RB1 locus.
45
  Patients with SCLC have a five-year survival rate of only 6%
I
, 
which can increase to 54% if detected at a localized stage.  Unfortunately, only 15% of SCLC 
are detected at the localized stage. This extreme aggressiveness is in stark contrast to the five-
year survival rates of tumors with lower rates of RB1 mutations such as breast, prostate, and 
colorectal cancers when detected at a localized stage, which are 99%, 100%, and 90%, 
respectively, according to the American Cancer Society Cancer Facts and Figures, 2014
I
. 
Interestingly, lung cancer survival rate triples to 18%
I
 in the non-small cell lung cancer (NSCLC) 
subtype, which usually bears wild type RB1 alleles but instead exhibits preferential loss of the 
p16
INK4A
 locus with consequent pRb hyperphosphorylation.
46
  The differences in survival rates 
between SCLC and NSCLC suggest that increased aggressiveness may be associated more with 
direct alterations of the RB1 locus than with chronic pRb hyperphosphorylation resulting from 
alterations in other loci. 
 This RB1 effect is also observed in epithelial cancers.  Although RB1 mutations are rare 
in prostate cancer, a recent analysis of 50 castration-resistant prostate cancer patients
47
 
demonstrated that patients with inactivating RB1 mutations have a 35 month reduction in median 
overall survival relative to patients with WT RB1 (p=0.025).   Specifically, the 16 patients with 
RB1 mutations had a median overall survival of 70 months, versus 105 months in 34 patients 
with WT RB1. 
 The data discussed above highlight the association between direct mutational targeting of 
the RB1 gene and high mortality as demonstrated by the low 5-year survival rates of pRb-null 
cancers.  Given that metastases indicate aggressiveness and cause over 90% of cancer deaths,
48
 
we propose that pRb deficiency leads to a proclivity for early metastasis, that is, for early 
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detachment of tumor cells from the primary tumor and invasion of adjacent and distal tissues.  If 
so, blocking cellular events associated with metastasis (eg, loss of cell polarity, epithelial-
mesenchymal transition (EMT), loss of cell adhesion) may be part of pRb´s tumor suppressive 
arsenal.  The first hints of a relation between pRb and  metastasis came from studies published 
over a decade ago implicating pRb in the stabilization of adherens junctions.  Disruption of these 
structures is part of EMT and contributes to metastases by facilitating detachment of cancer cells 
from the primary tumor mass.
38
  Early studies showed that retinoblastomas, osteosarcomas, and 
SCLC, known for their high frequencies of RB1 mutations, are composed of cells that lack stable 
adherens junctions.  In retinoblastoma, adherens junctions fail to anchor to the cortical actin 
cytoskeleton.
49
  In osteosarcoma and SCLC, adherens junction proteins are downregulated and 
aberrantly localized in the cytoplasm rather than at the cell membrane.
50,51
  Furthermore, a strong 
correlation was found in retinoblastoma and osteosarcoma between abnormal adherens junctions 
and invasive capacity,
49,50
 underscoring the notion that disruption of these structures is related to 
invasion, and for the first time, implicating pRb loss in invasive behavior. 
 These early studies linking pRb to adherens junction integrity remained largely ignored 
for years following their publication, possibly since they were mostly correlative and did not 
establish a causal relationship between pRb loss and cell adhesion perturbations.  An exception 
was a study showing that pRb inactivation by SV40 large T antigen in MDCK epithelial cells 
resulted in a mesenchymal conversion associated with invasiveness that could be reversed by 
pRb re-activation.
52
  This study also offered the first mechanistic explanation of pRb's 
involvement in cell adhesion by showing that pRb, together with the AP-2 transcription factor, 
activated transcription of the E-cadherin promoter in epithelial cells.
52
  It took approximately a 
decade for the next reports confirming the link between pRb and cell adhesion.  These studies 
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showed that pRb depletion disrupted cellular adhesion and induced a mesenchymal-like 
phenotype.  They further established that transcriptional regulation of E-cadherin expression by 
pRb is a molecular link between pRb and cell adhesion.
53,54
  Further implicating pRb loss in 
EMT, pRb depletion results in up-regulation of several EMT-related transcriptional factors 
including Slug and Zeb-1, which are known E-cadherin transcriptional repressors.
53,51
 
 The studies described above strongly implicate pRb loss as a promoter of metastasis of 
carcinomas, or epithelial tumors, specifically via the loss of epithelial markers such as E-
cadherin and the acquisition of mesenchymal and migratory phenotypes.  Additionally, it has 
been shown that OB-cadherin, the predominant osteoblast cadherin, is also transcriptionally 
regulated by pRb,
55
 implicating pRb loss in the molecular etiology of non-epithelial tumors such 
as osteosarcomas.  Conditional deletion of pRb in osteoblasts produces a 'cadherin switch' in 
which OB-cadherin is replaced by N-cadherin,
55
 suggesting that pRb promotes the expression of 
adhesion molecules characteristic of the fully differentiated state, regardless of cell type, while 
repressing the expression of cell adhesion genes related to an undifferentiated phenotype.  The 
global nature of pRb's influence on cell adhesion was revealed by microarray analyses 
comparing pRb-proficient versus pRb-deficient osteoblasts, which found that pRb affects the 
expression of a variety of cell adhesion genes beyond cadherins and that cellular processes 
related to cell adhesion are strongly affected by pRb.
55
  Integrins were also found among the cell 
adhesion genes whose expression is strongly affected by pRb, and cellular pathways involved in 
integrin-mediated cell-to-ECM adhesion were also found to be under pRb control.
55
  In a follow-
up study, it was shown that pRb induces transcription of integrin α10 in osteoblasts, regardless of 
pRb phosphorylation status, with a corresponding increase in osteoblast binding to a collagen 
substrate.
39
  This suggests that pRb mediates not only cadherin-dependent cell-to-cell adhesion, 
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but also promotes integrin-dependent cell-to-ECM adhesion.  Taken together, the studies 
summarized above indicate a strong influence by pRb on cell adhesion that can either be 
activating or repressive depending on the genes involved, up-regulating adhesion genes in 
differentiated cells (eg, integrin α10) while down-regulating expression of adhesion genes 
associated with invasiveness and metastasis (eg, N-cadherin). 
 pRb appears to regulate the formation of functional cell adhesive structures beyond 
transcriptional regulation of cell adhesion genes, including facilitating the assembly of cell 
adhesion gene products at the cell membrane.  In the absence of pRb, the Rho GTPase Rac1 and 
its effector the p21-activated protein kinase (Pak1) become up-regulated with consequent 
phosphorylation of the Merlin tumor suppressor at Serine 518 by Pak1, which in turn causes 
Merlin to detach from the cell membrane.
55
  Therefore, pRb seems to promote adherens junction 
assembly at the cell membrane by blocking the inactivating phosphorylation of Merlin by Pak1.  
Merlin is a membrane-bound tumor suppressor and cytoskeleton adapter that stabilizes adherens 
junctions by anchoring them to the cortical actin cytoskeleton under the plasma membrane.
56,57
  
Merlin loss, which is frequent in the human cancer syndrome Neurofibromatosis type 2 (NF2), 
results in adherens junction disruption with consequent inactivation of contact-dependent growth 
arrest.
56
  In summary, studies demonstrate that in the absence of functional pRb, transcription of 
adherens junction components as well as their assembly at the cell membrane are both 
compromised.  This explains the observation that in pRb-deficient tumors, such as 
retinoblastoma and osteosarcoma, not only do adherens junction proteins show diminished 
expression, but they also fail to anchor to the cell membrane instead showing aberrant 
cytoplasmic localization.
49-51
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 Invasiveness and metastases arise from a combination of loss of cell adhesion, onset of 
migration facilitated by cytoskeletal reorganization and loss of cell polarity, and the capacity to 
degrade basal laminae in order to escape the primary tumor site and penetrate adjacent tissues.  
The data summarized above link pRb loss predominantly to perturbations in cell adhesion, but 
pRb loss could exacerbate invasiveness by affecting other aspects of metastasis.  For example, 
pRb loss has been linked to increased expression of the matrix metalloproteinases (MMPs) that 
remodel the ECM during cell invasion and metastasis.
58,59
  MMP genes such as MMP9, MMP14, 
and MMP15, which are usually over-expressed in NSCLC, have been shown to be regulated by 
pRb.
59
  pRb reactivation was sufficient to inhibit MMP transcription, to reduce the invasion and 
migration of cancer cells in vitro, and to reduce metastatic foci development in a tail vein lung 
metastasis model in mice.
59
  pRb depletion also exacerbates the invasiveness of ErbB2-positive 
breast cancer, suggesting that pRb loss may play a predominant role in the progression of in situ 
breast ductal cell carcinoma to the invasive stages of the disease.
60
 
 The data implicating pRb control of cell adhesion in cultured cells are abundant and 
provide mechanistic insights that were lacking in early correlative studies.  There are also data 
providing insights into the consequences of pRb loss for in vivo tissue morphogenesis. When a 
mouse model of osteosarcoma was generated by conditionally knocking out RB1 in osteoblasts,
68
 
structural defects indicative of impaired osteoblast adhesion were observed in the calvaria of pRb 
knockout mice.  Specifically, pRb knockout mice lacked properly organized osteoblast layers 
and showed osteoblasts that had migrated away from their proper position in the calvaria and 
invaded the adjacent cartilage.
68
  pRb-deficient osteoblasts also expressed elevated levels of 
Ezrin, a membrane-cytoskeleton linker and osteosarcoma metastasis marker.
55,61,62
  Other mouse 
models of osteosarcoma based on abrogation of pRb function have resulted in mice that develop 
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fully penetrant, highly metastatic early onset osteosarcomas.
63
  Given the importance of cell-to-
cell adhesion for osteoblast differentiation, pRb loss can be predicted to alter osteoblast 
differentiation and lead to the formation of osteosarcoma.  Osteoblasts originate from pluripotent 
mesenchymal stem cells that differentiate into stroma, adipocytes, myoblasts, chrondroblasts, 
fibroblasts, or osteoblasts.
64,65
  Stem cells committed to osteoblastic differentiation are sorted 
from the rest of the mesenchymal precursors and align with, and adhere to, each other.  
Homotypic, cadherin-based cell-to-cell interactions play a major role in sorting the pluripotent 
stem cells into distinct lineages.  Consistently, osteoprogenitor cells express a spatio-temporally 
regulated repertoire of cadherins that provide cues for their alignment into a distinct 
subpopulation within the bone marrow that will later differentiate into mature osteoblasts.
66,67
  
Adherens junction loss in pRb-null osteoblasts is accompanied by abnormal expression patterns 
of the predominant osteoblast-specific cadherins OB- and N-cadherins, suggesting that the 
timing of cadherin expression during osteoblast differentiation can be altered by pRb loss.
55
  This 
in turn suggests that pRb is required to ensure that expression of specific cadherins proceeds with 
the right timing during differentiation, and that pRb loss could hamper proper homotypical 
intercellular contacts, resulting in defective osteoblast differentiation with consequent disruption 
of bone integrity and/or formation of bone tumors. Based on in vivo observations, it is plausible 
that pRb is instrumental in the orchestration of cell proliferation and cell adhesion as part of 
differentiation and bone morphogenesis. Disruption of which may be central to the molecular 
etiology of osteosarcomas, which are characterized by poor differentiation and high frequencies 
of RB1 mutations. 
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A LINK BETWEEN CELL CYCLE CONTROL AND CELL ADHESION 
 
 In metastatic cancer cells, adhesion is aberrantly regulated by a variety of pathways 
resulting in loss of cell-to-cell and cell-to-ECM contact and in dissemination of cancer cells 
throughout the body.  While more work is needed to elucidate those pathways, in many instances 
this loss of adhesion has been tied to cell-cycle regulators, including members of the pRb-E2F 
pathway. 
 Signaling from integrins through their downstream pathways occurs cooperatively 
through crosstalk with growth factor receptors and has been linked to a variety of pathways 
involved with cell cycle progression.  Integrin-mediated cell-to-ECM adhesion acts as a 
checkpoint for cell cycle entry.  For example, in early work using pRb positive LNCaP and pRb 
negative RU145 prostate epithelial cell lines, loss of β1 integrin contact to ECM inhibited G1 
CDK activity leading to an accumulation of hypophosphorylated pRb and subsequent Bcl-2 
mediated apoptosis.
68
  More recently, Wang et al.
69
 found that overexpression of integrin α5 and 
knockdown of integrin α6 decreased pulmonary metastasis of the highly invasive breast cancer 
cell line 4T1 by inhibiting entry to S-phase through p27 upregulation, resulting in 
downregulation of Cyclin E/CDK2 complexes.  They also found that this modulation of integrin 
expression upregulated E2F, which may then induce expression of Chk1 to regulate 
cdc25A/Cyclin E/CDK2/pRb in a feedback loop.  These findings implicate integrin α5 as a 
metastasis suppressor and α6 as a metastasis promoter in breast cancer.  For a comprehensive 
review of how integrins control downstream entry to cell cycle progression see the review by 
Moreno-Layseca and Streuli.
70
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 Expression of E2Fs1-3 was shown to indirectly increase integrin β4 mRNA, protein, and 
cell surface expression.
71
  These E2Fs were found to be downstream of active H-Ras in SUM-
159 breast carcinoma cells.  Integrin α6β4 has been previously shown to enhance carcinoma 
invasion, so the mechanism proposed by Yoon et al.
71
 links active H-Ras, active E2Fs and 
integrin α6β4 in a single pathway to promote invasion. 
 Long-term treatment of three NSCLC cell lines with recombinant CCN1 (Cysteine-rich 
61), a secreted matrix-associated molecule, led to permanent cell cycle arrest in G1.  Addition of 
CCN1 increased abundance of hypophosphorylated pRb and p53 and p21 accumulation.  A 
CCN1 mutant defective for binding integrin α6β1 and co-receptor heparan sulfate proteoglycans 
was incapable of inducing senescence.
72
 
 The finding that pRb's effect on integrin expression is unaltered by its phosphorylation 
state
39
 is particularly informative of the mechanisms linking pRb to cell adhesion and of the 
coupling between cell cycle and cell adhesion.  As discussed above, phosphorylation is a 
mechanism of regulation of pRb function that abrogates pRb's capacity to bind and block E2F 
transcription factors.  The integrin α10 findings39 suggest that regulation of cell cycle 
progression and cell adhesion by pRb may be mechanistically uncoupled since while pRb 
hyperphosphorylation abrogates pRb's capacity to bind E2F and repress the cell cycle, it leaves 
intact the capacity to induce integrin-mediated cell-to-ECM adhesion.  This could shed some 
light into the aggressive behavior of pRb-deficient tumors.  The tendency of pRb-deficient 
tumors to metastasize early in their development could be explained by the loss of both cell cycle 
control and cell adhesion resulting from pRb loss.  The residual pRb activity retained by tumors 
with chronically hyperphosphorylated pRb, while not enough to halt initial tumor growth, may 
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result in a less aggressive tumor and in deterring metastasis by helping to anchor the tumor 
structure. 
 The data discussed above expand the paradigm of pRb function beyond cell cycle to 
include roles in cell adhesion, and therefore implicate pRb loss in later stages of tumor 
metastasis.  Figure 2.1 shows a model depicting how pRb can integrate cell cycle control and 
cell adhesion. These dual roles of pRb mechanistically explain how impairment of pRb function 
contributes to the aggressive nature of some tumor types, expands pRb's arsenal of tumor 
suppressive abilities, and explains the potency of this preeminent tumor suppressor more 
adequately than the notion that pRb acts predominantly as a cell cycle repressor. 
 
Figure 2.1: Model illustrating the function of pRb in cell cycle control and cell adhesion.  
Pointed arrows indicate a stimulatory interaction.  Blunt arrows indicate pathway repression.  
Dotted lines represent indirect interaction or interactions via a mechanism that has not been fully 
elucidated.  
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TARGETING pRb LOSS AND ABERRANT ADHESION 
 
 The activity of the pRb kinases, the CDKs, is central to pRb pathway.  For these reasons, 
small molecule CDK inhibitors are being developed and examined in clinical trials for a number 
of malignancies.
73
 
 Aberrant adhesion has been determinant of potential treatment options in several cancers.  
For example, in erlotinib-resistant lung cancer cells harboring activating EGFR mutations, there 
was increased expression of Src, integrins β1, α2, and α5 along with increased adhesion.  
Silencing of integrin β1 restored erlotinib sensitivity.  There was also increased expression of 
integrins β1, α2, and/or α5 in refractory tumor samples from patients treated with erlotinib and/or 
gefitinib.
74
 
 Furanodiene, a natural terpenoid derived from Rhizoma Curcumae, was found to have 
anti-proliferative activity in 95-D human lung cancer cells when combined with paclitaxel.  
These effects included down-regulation of protein levels of Cyclins D1 and B1, CDK6, and c-
Myc, as well as down-regulation of expression of integrin β4, focal adhesion kinase, and 
paxillin.
75
  Previous studies had shown that combining furanodiene and paclitaxel had synergistic 
anti-proliferative effects in NCI-H1299 and 95-D human lung cancer cell lines,
76
 and that 
furanodiene decreased integrin β1 expression in breast cancer cells in a concentration-dependent 
manner.
77
 
 Unsurprisingly, aberrant integrin signaling has been implicated in several human cancers 
and specific therapies are being developed to target the integrin pathway including development 
of anti-integrin α4 antibodies (eg, Natalizumab currently being evaluated in over 80 clinical 
trials; http://clinicaltrials.gov), focal adhesion kinase (FAK) inhibitors (eg, GSK2256098 
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currently being evaluated in three clinical trials; http://clinicaltrials.gov), integrin-linked kinase 
(ILK) inhibitors, and RGD peptides (competitive inhibitors for the fibronectin-binding consensus 
sequence such as eptifibatide and tirofiban).  Unfortunately, integrins are also known mediators 
of cell adhesion-mediated drug resistance (CAM-DR).  Specifically, melanoma cells expressing 
α4β1 and α5β1 integrins are resistant to doxorubicin and melphalan once bound to their 
fibronectin ligands.
78
  This resistance is the result of cell cycle arrest in G1 and is associated with 
increased levels of the CDKN p27 and its inhibition of Cyclins A and E.
79
 
 "Ligand-induced" adhesion, an integrin-mediated Rap-1-independent pathway that allows 
unstimulated leukocytes to adhere to and migrate through exposed endothelial matrix or high-
density ligand, is CDK4-mediated, but pRb-independent.  CDK inhibitors were able to block this 
leukocyte adhesion and migration
80
. 
 The treatment options listed above are all designed to target either the pRb pathway or 
the process of adhesion.  With the new work being pioneered on the link between these two 
pathways, it is our hope that either combining these drug classes, or developing new drugs to 
specifically target this newly discovered link that treatment options will be more tailored to 
individual cancers and increasingly effective in the future.  
 
CONCLUSIONS: IMPLICATIONS FOR pRb AS A METASTASIS SUPPRESSOR 
 
 Recent work linking pRb to cell adhesion should reinvigorate the pRb field by 
challenging the classic paradigm of pRb acting predominantly as a cell cycle regulator.  New 
information about pRb, as well as other oncogenes and tumor suppressors discovered decades 
ago, continues to uncover novel effects and potentialities beyond cell cycle control. 
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 In the currently accepted model of tumor evolution, a step-wise accumulation of 
mutations results in the progressive acquisition of aberrant cellular behaviors, each behavior 
elicited by a particular mutation or sets of mutations.  Mutations that inactivate tumor 
suppressors like RB1 or that activate proto-oncogenes like KRAS would contribute to early stages 
of tumor evolution by conferring a proliferative advantage to incipient tumor cells.  These 
mutations target cell cycle control by rendering cells capable of bypassing proliferative arrest, 
contributing to unchecked tumor growth.  However, a paradigm in which pRb acts 
predominantly as a cell cycle repressor does not explain how pRb inactivation in early 
tumorigenesis would contribute to later stages of metastasis, particularly to the detachment of 
tumor cells from their original site and dispersion to distant tissues.  The current model thus 
mandates the acquisition of additional secondary mutations that confer metastasis potential at 
later stages of tumor evolution.  This multi-step model has been challenged, however, and 
deemed conceptually inconsistent since the additional genetic hits that confer metastatic 
capabilities at later stages of tumorigenesis do not necessarily exacerbate the proliferative 
advantage conferred by the initial hits that disrupt cell cycle control.
81
  In a tumor history that is 
essentially a micro-evolutionary process, if secondary metastasis-related mutations do not further 
enhance the previously acquired replicative advantage, the cells that acquired them will remain 
rare within the tumor mass, outcompeted by more proliferative counterparts.  Rather, it has been 
suggested that mutations acquired by incipient tumor cells early in tumorigenesis confer not only 
the replicative advantage that allows the initial tumor growth, but also later in tumorigenesis, the 
proclivity to metastasize.
81
  Thus, the tendency to metastasize could be determined by mutant 
alleles acquired early in tumor history.
81
  This revised model predicts that fewer mutations are 
required for a full-blown malignant phenotype if they target multifunctional genes such as RB1.  
27 
 
Several lines of evidence support this.  First, primary human breast cancers can shed malignant 
cells into the bone marrow even when tumors are small and well-localized; second, DNA 
microarray analyses reveal that metastatic tumor cells show gene expression profiles remarkably 
similar to the cells contained in the primary tumor from which they were derived; third, certain 
early gene-expression profiles in primary breast cancer tumors strongly predict metastasis and 
can be detected before metastasis actually occurs.
81-86
  A dual role for pRb in cell cycle and cell 
adhesion is fully consistent with a model of metastases arising from fewer mutations.  Thus, pRb 
inactivation enhances proliferative capacity and growth of tumor mass during early 
carcinogenesis, and also contributes to later stages of metastasis by promoting cell detachment 
from the primary tumor.  Further characterization of pRb's role in cell adhesion could contribute 
to what has been described as "the hope to achieve an understanding of the complex process of 
neoplastic transformation at the cellular level in terms of a small number of genetic changes."
87
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CHAPTER THREE: 
Expression of Integrin alpha 10 is Transcriptionally Activated by pRb in Mouse 
Osteoblasts and is Downregulated in Multiple Solid Tumors
IX
 
 
ABSTRACT 
 
 pRb is known as a classic cell cycle regulator whose inactivation is an important initiator 
of tumorigenesis.  However, more recently it has also been linked to tumor progression.  This 
study defines a role for pRb as a suppressor of the progression to metastasis by upregulating 
integrin α10.  Transcription of this integrin subunit is herein found to be pRb-dependent in 
mouse osteoblasts.  Classic pRb partners in cell cycle control, E2F1 and E2F3, do not repress 
transcription of integrin α10 and phosphorylation of pRb is not necessary for activation of the 
integrin α10 promoter.  Promoter deletion revealed a pRb responsive region between -108bp to -
55bp upstream of the start of the site of transcription.  pRb activation of transcription also leads 
to increased levels of integrin α10 protein and a greater concentration of the integrin α10 protein 
at the cell membrane of mouse osteoblasts.  These higher levels of integrin α10 correspond to 
increased binding to collagen substrate.  Consistent with our findings in mouse osteoblasts, we 
found that integrin α10 is significantly underexpressed in multiple solid tumors that have 
frequent inactivation of the pRb pathway.  Bioinformatically, we identified data consistent with 
                                                             
IX This chapter has previously been published in Cell Death and Disease (2013) 4, e98 and is reproduced here with 
permission from the Nature Publishing Group.  See Appendix A for details. 
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an 'integrin switch' that occurs in multiple solid tumors consisting of underexpression of integrins 
α7, α8, and α10 with concurrent overexpression of integrin β4.  pRb promotes cell adhesion by 
inducing expression of integrins necessary for cell adhesion to a substrate. We propose that pRb 
loss in solid tumors exacerbates aggressiveness by debilitating cellular adhesion, which in turn 
facilitates tumor cell detachment and metastasis. 
 
INTRODUCTION 
 
 The classic pRb pathway comprises pRb, the E2F family of transcription factors, cyclins 
(primarily D type), cyclin-dependent kinases (CDKs; primarily 4 and 6), and two families of 
CDK inhibitors (including p16Ink4a). In this classic view, pRb acts as a transcriptional repressor, 
binding E2F family members at the promoter site of E2F-regulated genes and maintaining 
transcriptional repression by blocking the transactivation function of E2F and by recruiting 
additional factors that actively repress transcription.
1
 Mitogenic signaling activates the formation 
of cyclin/CDK complexes, which are responsible for phosphorylating, and thus inactivating, 
pRb. Once hyperphosphorylated, pRb dissociates from E2F, which is now free to promote the 
transcription of E2F-regulated genes. 
 In contrast to its negative regulatory control over E2F-mediated transcription, pRb has 
also been found to positively regulate the expression of a number of genes. One such gene that 
was discovered to be positively regulated by pRb is E-cadherin, a cell surface adhesion protein 
that is a marker for epithelial cells.  Both pRb and c-Myc activate transcription of E-cadherin in 
epithelial cells in an AP-2 mediated manner.
2
 Similarly, pRb can bind members of the AP-1 
family of transcription factors, including c-Jun, at its AP-1 consensus sequence resulting in 
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stimulation of its transcriptional activity.
3
 Other genes known to be positively regulated by pRb 
include the anti-apoptotic gene, Bcl-2, which is activated in an Ap-2 dependent manner
4
 and the 
CDK inhibitor, p21, which is activated in an Sp1/Sp3 dependent manner
5
. The transcription 
factor Sp1 has also been found to be important in the upregulation of integrin α5 through 
interaction with, and activation by, the transcription factor ZEB2
6
. 
 pRb is inactivated either directly, through mutation of the Rb gene, or indirectly in the 
majority of human cancers.  Cancer types that have a greater than 90% frequency of pRb gene 
mutation (e.g. retinoblastoma, osteosarcoma, small cell lung cancer) are also characterized by 
disrupted cell-to-cell adhesion as mediated by adherens junctions.
7-9
  Previous work has shown 
that pRb-deficient osteoblasts do not undergo contact-dependent growth arrest, lack adherens 
junctions, and exhibit altered cadherin expression.
10
  This same work, via microarray, identified 
a number of genes involved in cell-to-extracellular matrix (ECM) adhesion that may also be pRb 
regulated.  One such gene that was identified was integrin α10. 
 Integrins are a family of heterodimeric proteins made up of an α and a β subunit.  They 
mediate adhesion of cells to ECM ligands and are unique among transmembrane receptors in that 
they have the ability to signal bidirectionally, carrying both mechanical and chemical signals.
11
  
Integrin α10 interacts exclusively with the β1 subunit to form α10β1 integrin.  This is one of four 
collagen-binding integrins and preferentially binds collagen type IV, the primary collagen type 
of the basal lamina, but also binds collagens type VI and II, the primary collagen types of the 
ECM of skeletal muscle and cartilage, respectively.
12
  Integrin α10 is found primarily in 
chondrocytes,
13,14
 but has also been found in chondrogenic mesenchymal stem cells, as well as 
the endosteum (cell lining between bone marrow and bone) and periosteum (cell lining outside 
the bone)
15
, areas rich in osteoblasts.  In these regions, osteoblasts are responsible for bone 
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development and produce osteoid, a matrix composed mainly of collagen type I.  A constitutive 
deletion of integrin α10 in mice resulted in a growth retardation of the long bones while 
maintaining a normal lifespan and fertility.
16
 
 We hypothesized that not only was integrin α10 present in osteoblasts, but that it was 
being regulated by pRb.  In this article we demonstrate that pRb transcriptionally activates 
integrin α10 and that the frequent loss of pRb in multiple solid tumors results in a dramatic 
downregulation of integrin α10.  pRb exerts its tumor suppressive effect primarily through 
repressing cell proliferation and inducing a post-mitotic state as well as driving differentiation.  
We would like to add 'maintaining cellular adhesion to the ECM' as a key tumor suppressive 
function of pRb as we suspect that the subsequent downregulation of integrin α10 is part of a 
greater 'integrin switch' that may have a vital role in the development of cancer metastasis.  Our 
study builds upon the growing literature that points to the loss of pRb as a key mediator of the 
progression to metastasis. 
 
MATERIALS AND METHODS 
 
Cell lines and drug treatment 
 Cell lines and the mice they were derived from were previously described by Sosa-Garcia 
et al.
10
  Briefly, primary osteoblasts were isolated and 3T3-immortalized from Rb1 conditional 
knockout embryonic mice and their Rb wild-type littermates to produce pRb null and pRb wild-
type MC3T3 cell lines, respectively.  They were grown in Minimum Essential Medium Alpha 
(MEM-α) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin.  
Approximately 2 x 10
6
 MC3T3 Rb wild-type cells were cultured in p60 plates and received 
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either a control treatment (complete media) or a drug treatment consisting of complete media 
supplemented with either 200 nM or 500 nM of the CDK 4/6 specific inhibitor, PD0332991 
(ChemiTek).  Cells were harvested 48 h after treatment and underwent RNA extraction followed 
by qRT-PCR as described below. 
 
Plasmid vectors 
 The pGL3-p27
17
, Rb wt LP, Rb 7 LP
18
, pEGFPc2 (GenBank Accession #U57606), 
pcDNA3-E2F1
19
, pcDNA3-E2F3
20
, CMV-Sp1(Plasmid 12097 purchased from 
http://www.addgene.org), and pGL3-CIITA-Δ195 (Gift from Ken Wright, Moffitt Cancer 
Center; Ghosh et al.
21
) have all been previously characterized.  The novel promoter plasmids 
were generated by PCR using the following primers: Δ590 forward (5'-
GAGAGGTACCTGTTGGGGGAAAGGTGCGGA-3'), Δ463 forward (5'-
GAGAGGTACCACAGGCAGTGACTCCCCAAAAGC-3'), Δ397 forward (5'-
GAGAGGTACCAGGTCACACAGTAGGACTGCCC-3'), Δ275 forward (5'-
GAGAGGTACCCCTACTTTCTGTTCCAAACTGGAGG-3'), Δ232 forward (5'-
GAGAGGTACCACCGTGCATAAAAGTAGCCTCAGAA-3'), Δ163 forward (5'-
GAGAGGTACCAGGGGGCAGCACCAAGGTAGAG-3'), Δ108 forward (5'-
GAGAGGTACCGGGCTCCCCACAGCTCCCTTC-3'), Δ55 forward (5'-
GAGAGGTACCTTAGCTGCCAGTGGGAGGGGG-3'), Reverse primer for all of the 
aforementioned (5'-GAGAAGATCTAGACTCCATGGGCGCTTGTCC-3').  The products were 
cleaved with KpnI and BglII and cloned into those sites of the pGL3-basic vector (Promega, 
Chicago, IL, USA). Site-directed mutants were created using the Δ590 plasmid altered with the 
following internal mutational primers and their reverse complements as reverse primers: Δ590-
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YY1 forward (5'-GTTATTTTGCATATCAACGGTTAAGATTAATAAG-3'), Δ590-HBP1(1) 
forward (5'-TGGAGGAAATTATTGGGCGAATAAACCGTGCATA-3'), Δ590-PAX6 forward 
(5'-TATTGAATAAATAAAATACGCATAAAAGTAGCCT-3'), Δ590-HBP1(2) forward (5'-
TTCCACCACCACTCCACGCCCATCCAACTTTATT-3'), Δ590-SP1 forward (5'-
GCTGCCAGTGGGAGGTTTAAGGATAGGAGGGAAA-3') 
 
Luciferase assays 
 Approximately 100,000 cells per well of MC3T3 Rb null cells were cultured in 24-well 
plates and transfected with a mixture containing 500 ng promoter construct, 50 ng Renilla 
luciferase reporter (pRL-TK, Promega), and 2.5 μg of either Rb expression plasmid or empty 
control vector (pEGFPc2) for an equal amount of DNA diluted in 100 μL serum free MEM-α for 
each transfection.  One microliter X-tremeGENE HP DNA transfection reagent (Roche 
Disgnostics, Indianapolis, IN, USA) was added to the DNA mixture and allowed to incubate for 
20 min before being added to the MC3T3 Rb null cells to a total volume of 600 μL (500 μL 
serum free medium plus 100 μL transfection mixture).  Cells were incubated with the 
transfection mixture for 4 h before being returned to complete media (MEM-α plus 10% FBS, 
1% penicillin/streptomycin).  Cells were harvested 48 hours after transfection and luciferase 
assays were performed using the dual-luciferase reporter assay system (Promega) following the 
manufacturer's protocol and read using a 20/20
n
 Luminometer (Turner Biosystems, Sunnyvale, 
CA, USA) with standard promega protocol DLR-O-INJ.  Experiments were done in triplicate.  
To control for transfection efficiency, firefly luciferase values were normalized to the values for 
Renilla luciferase. 
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Quantitative real-time PCR 
 Total cell RNA was harvested using the RNeasy Mini Kit (Qiagen, Carol Stream, IL, 
USA) following the manufacturer's instructions.  Reverse transcription reactions were carried out 
using iScript cDNA Synthesis Kit (Bio-Rad, Chicago, IL, USA).  Real-time PCR was performed 
using Bio-Rad iQ SYBR Green Supermix on a CFX96™ real-time PCR detection system (Bio-
Rad).  The following primers were used: Itgα10 forward (5'-GGCTCCAACAGTATCTATCC-
3'), Itgα10 reverse (5'-TGCTCTCACAACTTCTTCC-3'), GAPDH forward (5'-
AACGACCCCTTCATTGAC-3'), GAPDH reverse (5'-CTCCACGACATACTCAGCAC-3') 
 
Western blotting 
 Western blots were performed as previously described
22
.  Briefly, cell lysates were 
normalized for total protein content (35 μg) and subjected to SDS-PAGE.  Detection of proteins 
was accomplished using horseradish peroxidase-conjugated secondary antibodies and enhanced 
chemiluminescence (ECL; Amersham Biosciences, GE Life Sciences, Pittsburgh, PA, USA).  
Antibodies used include a mouse monoclonal antibody specific for endogenous pRb residues 
701-928 (9309; Cell Signaling), a goat polyclonal antibody corresponding to amino acids 528-
546 of Sp1 (sc-59-G; Santa Cruz Biotechnology), and a mouse monoclonal β-actin antibody 
(A5441; Sigma). 
 
Immunofluorescence 
 Immunofluorescence was performed as previously described
23
 without permeabilization.  
Briefly, cells were seeded in a Lab-Tak eight-chamber slide (Thermo Scientific, Waltham, MA, 
USA) 1 day before experimentation.  They were rinsed with PBS and fixed in 4% 
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paraformaldehyde followed by neutralization with glycine.  Cells were then sequentially 
incubated in 10% bovine serum albumin (BSA), either anti-integrin α10 (AB6030; Millipore) or 
anti-β-tubulin (2128S; Cell Signaling), followed by secondary AlexaFluor 488-conjugated goat 
anti-rabbit antibody (Invitrogen, Life Technologies, Grand Island, NY, USA) with added DAPI.  
This was followed by washing three times in PBS and covering the wells with Vectashield 
mounting media (Vector Labs, Burlingame, CA, USA) and coverslips.  Cells were imaged by the 
Moffitt Cancer Center Microscopy Core with a Leica SP5, Chicago, IL, USA AOBS tandem 
scanning inverted confocal microscope. 
 
Functional adhesion assays 
 Functional adhesion assays were performed as previously described
24
.  Briefly, 96-well 
Immunosorp (Nunc, Sigma Aldrich, St Louis, MO, USA) plates were coated with either 50 μL 
(40 μg/mL) of soluble Cultrex mouse collagen IV (BD Biosciences, San Jose, CA, USA) or BSA 
and allowed to evaporate overnight at room temperature.  Cells were washed once in serum-free 
MEM-α and resuspended at a density of 1 x 106 cells/mL with 1 x 105 cells added to each well.  
After 2 h of adhesion, unattached cells were removed by three washes with MEM-α, and 
adherent cells were fixed with 70% methanol for 10 min, dried, and subsequently stained with a 
solution of 0.02% crystal violet at 0.2% ethanol.  The stained cells were solubilized in 100 μL 
Sorenson solution and absorbance was read at 540 nm with an automated 96-well plate reader 
(VERSAmax, Sunnyvale, CA, USA).  Mean and SE values were calculated from the results in 
four independent wells.  Experiments were repeated three times and results of representative 
experiments are shown. 
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Mining public databases 
 Microarray studies conducted on cancers included in the National Cancer Institute's list 
of the 10 most common solid tumors (bladder, breast, colon and rectal, endometrial, kidney 
(renal cell), lung, melanoma, pancreatic, prostate, thyroid; 
http://www.cancer.gov/cancertopics/types/commoncancers) were analyzed using Oncomine 
(http://www.oncomine.org, Compendia Bioscience, Ann Arbor, MI, USA).  Data sets were 
ordered by under- or overexpression: P-value of integrin analyzed.  All known integrins with 
corresponding probesets were analyzed including integrins α1-11, α2B, αL, αM, αX, αV, αE, β1-
8, and βL1.  The only integrins found to be significantly under- or overexpressed in at least five 
of the seven data sets were integrins α7, α8, α10, and β4.  These four integrins were further 
analyzed using seven previously published microarray studies
25-31
 to evaluate their mRNA 
expression.  Six studies used Affymetrix human genome arrays with the probe set 216331_at for 
integrin α7, 214265_at for integrin α8, 206766_at for integrin α10, and 204990_s  for integrin β4 
with the exception of the Kaiser study which used probe set 211905_at for integrin β4.  The 
seventh study by Haqq et al. used a microarray of 20,862 cDNA targets representing 19,740 
unique genes (Research Genetics, Huntsville, AL, USA) with the probe set H44722 for integrin 
α10, and R87964 for integrin α8.  The study by Dyrskjot et al.32 included nine samples of normal 
bladder and five samples of normal bladder mucosa as well as 28 samples of superficial bladder 
cancer (superficial transitional cell carcinoma) comprising 15 tumor biopsies without 
surrounding carcinoma in situ and 13 tumor biopsies with surrounding carcinoma in situ.  The 
study by Haqq et al.
26
 included three samples of normal skin and six samples of melanoma.  The 
study by Hou et al.
27
 included 65 samples of normal lung and 27 samples of squamous cell lung 
carcinoma.  The study by Jones et al.
28
 included 23 samples of normal kidney and eight samples 
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of renal pelvis urothelial carcinoma (transitional cell cancers of the renal pelvis).  The study by 
Kaiser et al.
29
 included five samples of normal colon and 13 samples of colon mucinous 
adenocarcinoma.  The study by Landi et al.
30
 included 49 samples of normal lung and 58 samples 
of lung adenocarcinoma.  The study by Richardson et al.
31
 included seven samples of normal 
breast and 40 samples of ductal breast carcinoma. 
 
Statistical methods 
 A data set of non-small cell lung cancer (NSCLC) tumor and adjacent normal samples 
(GSE19188), was used to identify genes differentially expressed between tumor and adjacent 
normal. Sample GSM475805 was identified as a corrupt CEL file and excluded from all 
analyses.  Data were normalized with the RMA algorithm using the libaffy software
33
, and 
principle component analysis (PCA) was performed on the remaining 155 samples, using the 
Evince software (UmBio AB, Umeå, Sweden), to identify outliers. Three tumor samples 
(GSM475677, GSM475706, GSM475780) clustered in the middle of the adjacent normal 
samples, and one adjacent normal sample (GSM475666) fell within the tumor distribution.  
These samples were discarded for all further tumor versus adjacent normal analysis.  An 
additional six outlier adjacent normal samples (GSM475752, GSM475755, GSM475766, 
GSM475781, GSM475807, GSM475811) were identified as falling outside the otherwise tight 
adjacent normal distribution, lying between the adjacent normal and tumor clusters.  Subsequent 
analyses (data not shown) confirmed that these samples exhibit a more tumor-like gene 
expression profile than the other adjacent normals, and were thus discarded from further tumor 
versus adjacent normal analysis.  The final tumor plus adjacent normal data set, after discarding 
outliers, consisted of 58 adjacent normal and 87 tumor samples. Samples were then ranked by 
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their respective scores from the first principle component of a partial least squares discriminate 
analysis (PLS-DA) model, trained on tumor versus adjacent normal, to order them from most 
normal-like to most tumor-like global gene expression. 
 Statistical significance of data was calculated using a two-tailed Student's t-test in 
Microsoft Excel. 
 
RESULTS 
 
Integrin α10 expression is pRb-dependent in mouse osteoblasts 
 In previous work we examined the effects of pRb deficiency in mouse osteoblasts and 
identified a role for pRb as a regulator of cell adhesion
10
.  The microarray screen conducted as 
part of that work identified integrin α10 as a potential pRb-activated gene.  Integrin α10 
expression in osteoblasts has not been previously measured, but is known to be high in 
chondrocytes.  Both osteoblasts and chondrocytes are derived from a common progenitor cell so 
as a first step, we measured the endogenous expression levels of integrin α10 mRNA in mouse 
osteoblast MC3T3 cells, both wild-type and pRb null, at two different levels of confluency to 
verify that these cells are integrin α10 positive and that integrin α10 is indeed a pRb target 
(Figure 3.1).  We found that integrin α10 expression is much higher in pRb wild-type cells as 
compared with their pRb null counterparts.  Expression levels were also found to be highest at 
100% confluency likely due to increased ECM availability at higher cell densities.  The high 
levels of endogenous integrin α10 and the obvious changes in wild-type versus pRb null cells 
make MC3T3 mouse osteoblast cells an ideal model system to study changes in integrin function 
and expression engendered by pRb. 
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Figure 3.1 Expression of endogenous integrin α10 mRNA in MC3T3 wild-type and MC3T3 
pRb null cells.  RNA extraction was performed at two different levels of cell confluency 
followed by qRT-PCR with integrin α10 specific primers to determine expression levels relative 
to GAPDH.  The MC3T3 pRb null expression levels were set as one for each RNA extraction.  
Asterisk represents significant p-value: *=p<0.05. 
 
Phosphorylation of pRb is not necessary for activation of integrin α10 promoter 
 We hypothesized that pRb was regulating integrin α10 at the level of transcription.  In 
order to test this, we defined a putative integrin α10 promoter as the 590 base pairs of DNA 
immediately upstream of the start of the site of transcription using the fully sequenced 
chromosome 3 from the Mouse Genome Project (NCBI Reference Sequence: NC_000069.6).  A 
variety of constructs were made of this integrin α10 putative promoter (Figure 3.2) and were 
determined to be active.  When acting as a regulator of cell cycle progression, the 
phosphorylation status of pRb determines whether or not cells proceed through the G1 
checkpoint.  Upon phosphorylation by cyclin D/CDK4/6 complexes, pRb becomes inactivated 
and allows progression to S-phase.  To determine if phosphorylation status altered the role of 
pRb in regulating expression of integrin α10, and to narrow down the minimal responsive region 
of the integrin α10 promoter, three deletion constructs of the integrin α10 promoter were 
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transfected into MC3T3 cells along with the wild-type pRb large pocket or the non-
phosphorylatable pRb large pocket (Figure 3.3A).  Phosphorylation was not necessary for the 
activation of the integrin α10 promoter.  In order to confirm that differences in activation were 
due to intrinsic properties of the pRb constructs and not due to increased transfection efficiency 
of either one, a western blot was conducted and the constructs expressed comparable levels of 
protein (Figure 3.3B).  As a final confirmation that the phosphorylation of pRb is not necessary 
for upregulation of integrin α10 MC3T3 pRb wild-type cells were treated with two doses of 
PD0332991, a drug specific for CDKs 4 and 6, the two CDKs responsible for phosphorylating 
pRb (Figure 3.3C).  Endogenous levels of integrin α10 mRNA were measured 48 h after 
application of the drug.  Cells treated with the drug did not exhibit any inhibition of integrin α10 
mRNA expression as compared with the untreated control cells. 
 
E2F1 and E2F3 do not repress transcription of integrin α10 
 One of the best characterized roles of pRb is as a regulator of transcription involving its 
interaction with the E2F family of transcription factors.  E2F involvement would likely be the 
result of the E2F transcription factor repressing transcription of the integrin α10 promoter.  
Addition of pRb would activate the integrin α10 promoter through alleviating this E2F-mediated 
repression.  Previous studies have identified E2F1 as a repressor of the Mcl-1 promoter
19
.  We 
explored the potential of E2F1 and E2F3 to repress the integrin α10 promoter in the absence of 
pRb.  The addition of E2F1 and E2F3 expression plasmids did not result in repressed 
transcription (Figure 3.4) suggesting that pRb is acting through a non-E2F mediated pathway. 
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Figure 3.2 Schematic of the integrin α10 promoter.  (A) Schematic shows the eight 5’-nested 
deletion constructs characterized (Δ590, Δ463, Δ397, Δ275, Δ232, Δ163, Δ108, Δ55), the five 
site-directed mutants of the Δ590 construct (Δ590-YY1, Δ590-HBP1(1), Δ590-PAX6, Δ590-
HBP1(2), Δ590-SP1) with their 4 base pair substitutions, the putative transcription factor binding 
sites (underlined), and the primers used for cloning (highlighted in gray).  All constructs begin at 
the base pair by which they are named (upstream relative to the start of the site of transcription) 
and end at +60.  
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Figure 3.3  Effect of pRb phosphorylation status on integrin α10 transcription.  (A) Three 
integrin α10 promoter deletion constructs (Δ590, Δ463, Δ163) and a p27 promoter construct 
control were co-transfected separately with either pEGFPc2 (control), pRb wild-type large 
pocket (Rb wt LP), or pRb non-phosphorylatable large pocket (Rb 7 LP) into MC3T3 pRb null 
cells.  Promoter activation was measured by luciferase activity.  p27 control activity is set to one.  
(B) Western blot of control (pEGFPc2), pRb wild-type large pocket (Rb wt LP), and pRb non-
phosphorylatable large pocket (Rb 7 LP) transfected into MC3T3 pRb null cells.  Blot was 
probed for pRb (9309; Cell Signaling) and β-Actin (A5441; Sigma).  (C) Expression of 
endogenous integrin α10 mRNA in MC3T3 wild-type cells treated with the CDK 4/6 specific 
drug, PD0332991 at two different doses (200nM and 500nM).  RNA extraction was performed 
48 hours post drug treatment followed by qRT-PCR with integrin α10 specific primers to 
determine expression levels relative to GAPDH.  The untreated MC3T3 pRb wild-type 
expression levels were set as one.  Asterisks represent significant p-values as follows: *=p<0.05, 
**=p<0.01, and ***=p<0.001. 
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Figure 3.4  Effect of E2F1 and E2F3 on Integrin α10 promoter activation.  Three integrin 
α10 promoter deletion constructs (Δ590, Δ463, Δ163) and a p27 promoter construct control were 
co-transfected separately with either pEGFPc2 (control), E2F1pcDNA3 (E2F1), or 
E2F3pcDNA3 (E2F3) into MC3T3 pRb null cells.  Promoter activation was measured by 
luciferase activity.  p27 control activity is set to one.  No changes were statistically significant. 
 
Exploring the possible involvement of other transcription factors 
 According to the Biological General Repository for Interaction Data sets (BioGRID; 
http://www.thebiogrid.org),
34
 human pRb associates with 145 unique interactors.  Bioinformatic 
analysis of the integrin α10 promoter was conducted to look for putative binding sites for these 
145 interactors using the Genomatix program MatInspector (Genomatix Software GmbH, 
Munich; http://www.genomatix.de; Cartharius et al.
35
 and Quandt et al.
36
).  This analysis 
revealed putative transcription factor binding sites for known pRb interacting transcription 
factors YY1, yin-yang 1, from -321 to -301bp, HBP1, high-mobility group box transcription 
factor 1, from -248 to -224bp (HBP1(1)), PAX6,  paired box homeotic gene-6, from -241 to  
-223, a second HBP1 site from -88 to -64bp (HBP1(2)), and Sp1, specificity protein 1, from -42 
to -26bp (Figure 3.2).  We decided to further analyze the potential involvement of Sp1 as it is 
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not only known to interact with pRb, but has previously been shown to have a role in the 
upregulation of integrin α5 along with ZEB26.  Additionally, this site identified on the mouse 
promoter was also conserved on the human promoter with a putative binding site of base pairs 
 -17 to -1 with respect to the start of the site of transcription (data not shown).  We explored the 
possibility that Sp1 could act with pRb as a co-activator of transcription of the integrin α10 gene.  
Sp1 was added in the presence and absence of pRb to three integrin α10 promoter constructs in 
MC3T3 pRb null cells looking for a synergistic activation when both Sp1 and pRb were added, 
however no activation was observed to correspond with the addition of Sp1 (data not shown). 
 As there was no evidence of Sp1 having a role in the activation of integrin α10, we 
decided to look at the other putative pRb interacting transcription factor binding sites on the 
integrin α10 promoter. Site-directed mutants were made in which the four base pairs most critical 
for the binding of the transcription factor to the promoter (the 'canonical binding site' as 
determined by Genomatix) were mutated (Δ590-YY1, Δ590-HBP1(1), Δ590-PAX6, Δ590-
HPB1(2), and Δ590-Sp1).  In addition to the site-directed mutants, a series of progressive 
deletion mutants were made in which each successive deletion removed one of the putative 
transcription factor binding sites (Δ397, Δ275, Δ232, Δ108, and Δ55).  The site-directed 
mutation of individual binding domains did not reveal a single motif responsible for pRb 
activation of the integrin α10 promoter (Figure 3.5B) pointing to either a lack of individual 
importance of these transcription factors in the activation of the integrin α10 promoter, or 
continued binding despite the mutated base pairs suggesting that they were not, in fact, the 
canonical binding site.  Interestingly, the progressive deletions of the integrin α10 promoter 
resulted in progressively diminished transcriptional activation, all the while not losing the 
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activating effect of pRb up until the Δ55 construct suggesting a pRb responsive region between   
-108bp to -55bp upstream of the start of the site of transcription (Figure 3.5C). 
 As all of the constructs and controls are activated by the addition of pRb, a control 
experiment was conducted using the promoter of CIITA, the class II major histocompatibility 
complex transactivator, a gene not known to be pRb regulated.  As expected, the addition of pRb 
did not cause any significant change in CIITA transcription (Figure 3.5A). 
 We used a bioinfomatic approach to create the list of transcription factors that were 
potentially involved in activating integrin α10, but relying on the computer algorithm  and 
exploring only the region directly upstream of the start of the site of transcription may have 
excluded a key transcription factor.  A different starting point could have been a literature search, 
or including a greater region of the upstream sequence to search.  With this list in mind, 
additional experiments that could have been conducted to determine the involvement of other 
transcription factors include using siRNA to deplete the transcription factors to see if any 
significant decrease in integrin α10 activation occurred.  Conversely, only Sp1 DNA was added 
into the luciferase experiments to see if it activated the expression of integrin α10, but other 
transcription factor DNAs could also have been added.  An EMSA could have been used to 
determine if any of these transcription factors bind to the promoter sequence of integrin α10.  
Although not shown in any figures, multiple ChIP experiments were conducted to observe pRb 
binding along the integrin α10 promoter.  These same samples could have immunoprecipitated 
using antibodies directed against the putative transcription factors involved to show their binding 
to the integrin α10 promoter.  This binding could be in complex with pRb, a possibility that 
could be explored using co-immunoprecipitation to determine if the transcription factors were 
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directly bound to pRb.  Additional mutagenesis experiments could have been used to confirm the 
specific promoter regions necessary for activation by these transcription factors. 
 
pRb wild-type osteoblasts exhibit higher protein levels and adhesion of Integrin α10 
compared with matched pRb null cells 
 pRb-activated expression of integrin α10 mRNA is effectively translated into higher 
levels of integrin α10 protein as visualized by immunofluorescence (Figure 3.6A).  Integrin α10 
protein in pRb wild-type osteoblasts is located in high concentrations at the cell membrane 
forming a well-defined cellular margin. The matched pRb-null osteoblasts are characterized by 
lower levels of membranous integrin α10 protein with irregular signal at cell margins.  For both 
cell types nuclear staining with the integrin α10 antibody is likely nonspecific.  No differences in 
β-tubulin staining levels and patterns were observed between the two cell lines. 
 Next, we decided to test the functionality of the integrin α10 protein in both the pRb 
wild-type and pRb null osteoblasts.  As expected, the higher levels of integrin α10 protein in pRb 
wild-type osteoblasts directly corresponded to a statistically significant change of approximately 
47% greater binding to collagen IV as compared with matched pRb null cells (Figure 3.6B).  
This indicates that not only is more integrin α10 protein present in pRb wild-type osteoblasts, but 
this protein is functional and maintains cellular adhesion to ECM substrate that is lost when pRb 
is no longer present. 
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Figure 3.5  Effect of pRb on activation of site-directed and deletion mutants of the integrin 
α10 promoter.  (A) A CIITA promoter construct and a p27 promoter construct control were co-
transfected separately with either pEGFPc2 (control) or pRb wild-type large pocket (Rb wt LP) 
into MC3T3 pRb null cells.  Promoter activation was measured by luciferase activity.  p27 
control activity is set to one.  (B) An integrin α10 promoter construct (Δ590), five site-directed 
mutants of that construct (Δ590-YY1, Δ590-HBP1(1), Δ590-PAX6, Δ590-HBP1(2), Δ590-SP1) 
and a p27 promoter construct control were co-transfected separately with either pEGFPc2 
(control) or pRb wild-type large pocket (Rb wt LP) into MC3T3 pRb null cells.  Promoter 
activation was measured by luciferase activity.  p27 control activity is set to one.  (C) Six 
integrin α10 promoter deletion constructs (Δ590, Δ397, Δ275, Δ232, Δ163, Δ55) and a p27 
promoter construct control were co-transfected separately with either pEGFPc2 (control) or pRb 
wild-type large pocket (Rb wt LP) into MC3T3 pRb null cells.  Promoter activation was 
measured by luciferase activity.  p27 control activity is set to one.  Asterisks represent significant 
p-values as follows: *=p<0.05, **=p<0.01, and ***=p<0.001. 
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Figure 3.6 Effect of pRb on Integrin α10 protein levels and function.  (A) MC3T3 pRb wild-
type and pRb null cells were probed with antibodies against β-tubulin (2128S; Cell Signaling) 
and integrin α10 (AB6030; Millipore) (green) and stained with DAPI (blue; nuclei).  They were 
then examined using confocal immunofluorescence microscopy.  Representative images are 
shown. (B) MC3T3 pRb wild-type and pRb null cells were incubated with either collagen IV or 
BSA substrate and allowed to adhere.  Attached cells were permeabilized and stained with 
crystal violet.  Absorbance at 540nm was measured.  Asterisk represents significant p-value: 
*=p<0.05. 
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Identification of an 'integrin switch' that occurs in multiple solid tumors 
 Analysis of integrin expression in public databases of the most common solid tumors led 
to the identification of a four integrin signature that appears as consistently significant changes in 
mRNA expression levels between tumors and their matched normal tissues.  Specifically, the 
signature consists of overexpression of integrin β4 and underexpression of integrins α7, α8, and 
α10 (Table 3.1, Figure 3.7A-D).  Increased expression of integrin β4 has also previously been 
linked to metastasis in human osteosarcoma cells.
37
 
 Due to the relative rarity of osteosarcoma and the propensity to treat the disease before 
tumor resection, no data on integrin α10 expression in tumor and matched normal tissue could be 
obtained.  Instead, seven solid tumor types from the National Cancer Institute's list of the ten 
most common solid tumors were examined, including two types of lung cancer, and all exhibited 
significantly underexpressed integrin α10 as compared to their matched normal control tissues 
(Table 3.1, Figure 3.7E-H).  Specifically, ductal breast carcinoma, the most common type of 
breast cancer, had the largest fold-change
31
 (Figure 3.7G) followed by melanoma
26
 (Figure 
3.7H).  Squamous cell lung carcinoma, a subtype of non-small cell lung cancer (85% of all lung 
cancers) which accounts for 25-30% of all non-small cell lung cancers, had the third highest 
fold-change
27
 (Figure 3.7F).  Next was superficial bladder cancer, which accounts for 80% of 
bladder cancers
32
.  Renal pelvis urothelial carcinoma was next
28
; this study also showed 
downregulation or no change in renal pelvis urothelial cancer in all of the adhesion genes 
analyzed (e.g. ADAM12, ADAMTS5, ADAM9, TNFAIP6, GNRH2, CD47, CD36, ICAM1, 
CD96, CD99, SCARB1, CDW52).  Sixth was lung adenocarcinoma, which accounts for roughly 
50% of all non-small cell lung cancers
30
 (Figure 3.7E).  Finally, colon mucinous 
adenocarcinoma was seventh.
29
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Table 3.1 Integrin expression in seven common solid tumor types. 
 Integrin α7 Integrin α8 Integrin α10 Integrin β4 
Database Fold 
Change 
p-value Fold 
Change 
p-value Fold 
Change 
p-value Fold 
Change 
p-value 
Dyrskjot Bladder 3 -1.587 1.63E-05 -1.475 2.25E-04 -1.604 3.99E-07 2.313 1.82E-05 
Haqq Melanoma NC 2.68E-01 -1.504 3.00E-03 -3.471 2.04E-04 N/A N/A 
Hou Lung -1.734 1.64E-14 -5.742 1.91E-15 -1.828 2.88E-18 3.591 8.92E-10 
Jones Renal -1.523 2.45E-05 -3.993 7.00E-17 -1.499 5.91E-10 2.500 2.00E-03 
Kaiser Colon NC 9.40E-02 -1.494 1.00E-03 -1.222 6.09E-06 2.852 5.81E-05 
Landi Lung -1.239 1.01E-07 -2.375 4.58E-17 -1.357 9.02E-14 1.588 3.36E-07 
Richardson Breast -5.362 3.41E-06 NC 1.70E-02 -3.491 2.00E-06 -2.735* 1.86E-08 
Data comes from OncomineTM (www.oncomine.org, Compendia Bioscience, Ann Arbor, MI). 
The fold change value is determined by comparing the means of the two classes in an analysis on 
a log2 scale and then converting that difference to a linear scale (www.oncomine.org).  NC = no 
significant difference in expression between normal and tumor tissue.  N/A = this study did not 
have a probe for the gene of interest.  Only one significant change occurred in the opposite 
direction of the other six datasets and is denoted with an asterisk. 
 
 
CONCLUSIONS 
 
 In this study we have demonstrated that integrin α10 is expressed in mouse osteoblasts 
and that the expression of this gene is activated at a transcriptional level by pRb.  This activation 
of expression directly leads to increased integrin α10 protein levels and greater adhesion to a 
collagen substrate.  Our analysis of publically available databases revealed that integrin α10 is 
significantly downregulated in tumor tissue compared with normal in multiple solid tumors.  
These findings point to an important role for changes in integrin α10 expression during disease 
progression. 
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Figure 3.7 Changes in integrin expression occur in multiple solid tumors.  (A-D) The 
GSE19188 dataset of NSCLC tumor and adjacent normal samples was ranked from most normal 
to most tumor-like.  Samples 1-58 are the adjacent normals (black diamonds) while samples 59-
145 represent tumor samples (light gray diamonds). Gene expression was determined via 
microarray for integrin α7 using probe 216331_at (A), α8 using probe 214265_at (B), α10 using 
probe 206766_at (C), and β4 using probe 204990_s_at (D). (E-H) Oncomine™ 
(www.oncomine.org, Compendia Bioscience, Ann Arbor, MI) was used for analysis and 
visualization of integrin α10 expression in four common solid tumor types.  Datasets were 
ordered by under-expression: P-value of Itga10.   (E) Analysis of integrin α10 expression in 
normal lung (n=49) vs. lung adenocarcinoma (n=58) from the Landi Lung database.  (F) 
Analysis of integrin α10 expression in normal lung (n=65) vs. squamous cell lung carcinoma 
(n=27) from the Hou Lung database.  (G) Analysis of integrin α10 expression in normal breast 
(n=7) vs. ductal breast carcinoma (n=40) from the Richardson Breast 2 database.  (H) Analysis 
of integrin α10 expression in normal skin (n=3) vs. melanoma (n=6) from the Haqq Melanoma 
database. 
   
 The downregulation of integrin α10 following pRb loss may be part of a larger oncogenic 
event in which cellular differentiation is lost.  Differentiation has previously been measured as 
part of a 'cadherin switch' in which epithelial cells lose their epithelial phenotype and become 
more mesenchymal in character.  We propose that there is a simultaneous 'integrin switch' 
involving the downregulation of integrins α10, α7, α8, and potentially other positive prognostic 
integrins with concurrent upregulation of less favorable integrins, including integrin β4, that 
results in a loss of adhesion to the local extracellular matrix allowing previously anchored cells 
to metastasize.  As a highly tissue specific integrin, loss of α10 may be associated with a loss of 
differentiation.  There is potential to use integrin α10 levels as a prognostic marker.  High levels 
indicate a tumor that has retained differentiation and will likely have better overall survival while 
decreased expression levels are an indicator of a more advanced disease state in which pRb has 
been lost or mutated. 
 This study builds upon our previous work defining a role for pRb as a regulator of mouse 
osteoblast cell adhesion
10
 and adds to the growing literature that links pRb to the metastatic 
cascade.
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CHAPTER FOUR: 
The Molecular Biology and Therapeutic Implications of STK11/LKB1 Mutations in Lung 
Cancer
X
 
 
ABSTRACT 
 
 Lung cancer is the leading cause of cancer-related death in the U.S. and additional 
targeted therapies are desperately needed to treat these patients.  STK11 is the third most 
frequently mutated gene in lung adenocarcinoma following only KRAS and TP53, yet its 
mutational status is not currently clinically evaluated and no therapies have been approved to 
specifically target its pathway.  A deep understanding of the complex pathways controlled by 
STK11 and their alterations in cancer are required to develop effective therapies for patients with 
loss-of-function mutations.  In this article we present the current understanding of STK11, 
focusing on its molecular biology and therapeutic implications, including a compilation of 
studies evaluating STK11 somatic mutations in human lung cancer tissue and how the frequency 
of these mutations varies across histological subtypes and patient populations.  Finally, we 
review the strategies being used to target STK11-deficient cancers at the clinical trial, pre-
clinical, and basic science levels as well as proposing potential new therapies that might benefit 
this patient population. 
 
                                                             
X This chapter will be submitted for publication.  See Appendix A for details. 
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OVERVIEW 
 
 In the U.S., lung cancer is the second most diagnosed cancer in both men and women 
following only prostate cancer and breast cancer, respectively.
1
  Although the incidence rate has 
been declining in men over the past two decades, in women the incidence rate has just recently 
started to decrease.  Lung cancer is the leading cause of cancer-related death among both men 
and women.  Non-small-cell lung cancer (NSCLC) represents more than 80% of lung cancer 
diagnoses and has an overall 5-year survival rate of approximately 16%, which decreases 
precipitously among patients diagnosed with late stage disease.
2
 
 Traditionally, decisions on lung cancer treatment have been based on clinical 
characteristics such as stage at diagnosis, performance status of the patient, and tumor histology.  
More recently, however, treatment strategies involve the subdivision of NSCLC into molecular 
subsets based on gain-of-function mutations in oncogenes and loss-of-function mutations in 
tumor suppressors.  Many of these alterations occur disproportionately across lung tumor 
histopathologies,
3-5
 which likely indicate differences in carcinogenesis and cell type of origin.  
Mutations in these genes confer an advantage to tumor cells by activating signaling pathways 
crucial for cancer cell proliferation and survival.  Loss-of-function mutations in tumor suppressor 
genes are more common events than gain-of-function mutations in oncogenes, but have 
traditionally been much more difficult to treat therapeutically as restoring their function would 
involve delivery of wild type DNA to tumor cells and no viable delivery systems have been 
developed to date.  Instead, the most effective therapies are small molecule inhibitors that block 
gain-of-function activity, especially of proteins on the cell membrane.  Drugs designed to 
specifically inhibit these molecular targets have significantly extended survival times for NSCLC 
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patients whose tumors harbor these gain-of-function mutations.
6
  Restoring the function of 
mutated tumor suppressors is generally achieved through targeting key downstream signaling 
pathways that exhibit increased activity when the tumor suppressor is lost.  Development of 
therapeutic regimes to replace the activity of tumor suppressors requires a deep understanding of 
the far-reaching effects of their loss-of-function mutations and studying the molecular biology of 
these key proteins is central to this strategy.  STK11 is one of these key tumor suppressors. 
 The STK11 gene encodes a tumor suppressor located on chromosome 19p13.3 that 
encodes the serine/threonine protein kinase also known as liver kinase β1 (LKB1).  The gene 
spans 23kb and is made up of nine coding exons (exons 1-9) and a final non-coding exon (exon 
10).  Germline mutations in STK11 were first identified in patients with Peutz-Jeghers 
syndrome,
7
 a rare autosomal dominant disorder which is associated with an increased risk of 
gastrointestinal and other malignancies,
8,9
 with over 80% of patients developing cancer by the 
age of 70.
10
  Studies have also found that STK11 somatic mutations are quite common in 
NSCLC, especially among adenocarcinomas, suggesting an important role for STK11 in lung 
tumorigenesis.
11-18
  In this article we review the current evidence regarding the role of STK11 
mutations in lung cancer focusing on the molecular biology and therapeutic implications. 
 
STUDIES OF STK11 MUTATIONS IN HUMAN LUNG CANCER 
 
 Although rarely mutated in most human cancers, STK11 is the third most frequently 
mutated gene in lung adenocarcinoma after KRAS and TP53.
5,11,15,16,19
  Table 4.1 summarizes 
studies that have generated STK11 somatic mutation data from human lung cancer tissue.  The 
collection of these data from primary tumor samples is often complicated by the fact that tumor 
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suppressor genes such as STK11 can undergo mutational and deletional events that can be missed 
due to normal tissue contamination, resulting in marked underrepresentation.  With that in mind, 
the frequency of STK11 mutations in these studies range from 0.6% to 44.4%.  Two studies 
reported the frequency of STK11 mutations across adenocarcinoma subtypes,
5,20
 some analyzed 
the overall frequency of STK11 mutations across multiple histological subtypes,
21-25
 while other 
studies reported STK11 inactivating mutations in other lung cancer histology subtypes (e.g., 19% 
of squamous cell carcinomas, 14% of large cell carcinomas, and 25% of adenosquamous 
carcinomas).
14-16,21,26,27
  The spectrum of mutation frequency across histological subtypes is 
consistent with previously published data from mouse models where STK11 deficiency altered 
the resulting spectrum of tumor histology.
12
  Specifically, STK11-deficient tumors were found in 
adenocarcinoma, squamous, and large cell carcinoma, whereas the tumors in other genetic 
models of murine lung cancer were solely adenocarcinoma histology.
12
  None of the studies 
found any associations with overall survival which contrasts what is known about EGFR and 
KRAS mutations.  EGFR mutations are associated with sensitivity to EGFR-tyrosine kinase 
inhibitors, namely gefitinib and erlotinib,
28
 but it is also known that patients with EGFR mutant 
tumors have better overall survival regardless of treatment,
29
 while lung cancer patients with 
KRAS mutant tumors are associated with worse overall survival, especially in patients with 
adenocarcinoma and early stage disease.
30
  However, STK11 inactivation has been shown to be a 
prominent biomarker for poor outcome in cervical cancer, with a median survival of only 13 
months for patients with STK11-deficient tumors versus greater than 100 months for wildtype 
tumors.
26
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Table 4.1: Studies reporting STK11 somatic mutations in human lung cancer. 
REFERENCE HISTOLOGY ASSAY STAGE GENDER N=  ≥1 STK11 
MUTATIONS 
(%) 
ASSOCIATIONS 
Avizienyte et 
al.
31
 
12 Squamous cell, 
3 Large cell carcinoma, 
1 Small cell carcinoma, 
12 Adenocarcinoma 
SSCP 
analysis 
NR NR 1 Adenocar. 
(12%) 
NR 
Sanchez-
Cespedes et al.
11
 
Adenocarcinoma Manual 
sequencing 
NR NR 6 (30%) NR 
Matsumoto et 
al.
15
 
106 Adenocarcinoma, 
24 Adenocarcinoma, 
25 Brain metastases 
Manual 
sequencing 
Stage I only, 
Stage I-III, 
Mets 
NR 1 (0.9%) 
3 (12.5%) 
3 (12%) 
STK11 mutation 
only men/smokers; 
No EGFR/ STK11 
double mutants 
Onozato et al.
32
 81 Adenocarcinoma, 
14 Squamous cell, 
1 Adenosquamous, 
2 Large cell carcinoma, 
1 Small cell carcinoma, 
1 Carcinoid 
Manual 
sequencing 
57 Stage I, 
13 Stage II, 
27 Stage III, 
3 Stage IV 
59 Males, 
41 Females 
3 (3%) All 3 patients with 
STK11 mutations 
were male smokers 
Ji et al.
16
 80 Adenocarcinoma, 
42 Squamous cell, 
5 Adenosquamous, 
10 Large cell carcinoma, 
6 Unknown 
Direct exon 
sequencing 
and copy 
loss by 
MLPA 
NR NR 37 (26%) NR 
Lee et al.
33
 105 Adenocarcinoma, 
54 Squamous cell 
Direct 
sequencing 
82 Stage I, 
77 Stage II-
IV 
108 Males, 
51 Females 
1 (0.6%) 824delC in male 
smoker with 
adenocarcinoma 
Wilkerson et 
al.
20
 
Adenocarcinoma Direct 
sequencing 
NR NR 9 (12.3%) No association 
with survival 
Gill et al.
25
 68 Adenocarcinoma, 
49 Squamous cell 
Direct 
sequencing 
78 Stage I, 
47 Stage II-
IV 
79 Males, 
45 Females 
7/62 (11.4%)* 6 mutants were 
Adenocarcinoma; 
1 was Squamous 
Okuda et al.
34
 Adenocarcinoma Direct 
sequencing 
105 Stage I, 
24 Stage II, 
38 Stage III, 
7 Stage IV 
157 Males, 
17 Females 
5 (2.9%)** No mutations 
among light 
smoker males. 
Koivunen et 
al.
21
 
207 Adenocarcinoma, 
92 Squamous cell, 
9 Adenosquamous 
Direct 
sequencing 
188 Stage I, 
59 Stage II, 
47 Stage III, 
8 Stage IV 
187 Males, 
187 Females 
34 (11%) No association 
with survival; 
Caucasians and 
smokers more mut. 
Strazisar et al.
22
 51 Adenocarcinoma, 
67 Squamous cell, 
11 Large cell carcinoma 
DHPLC 
mutation 
screening 
NR 107 Males, 
22 Females 
3 (2.3%) All 3 mutations 
were in 
Adenocarcinoma 
Tan et al.
24
 206 Adenocarcinoma, 
24 Large cell carcinoma 
Sequenom 
LungCarta 
panel 
NR 158 Males, 
72 Females 
13 (5.7%) No association 
with overall 
survival 
Tam et al.
35
 Adenocarcinoma cDNA 
sequencing 
31 Stage I, 
8 Stage II, 
5 Stage III, 
1 Stage IV 
16 Males, 
29 Females 
20 (44.4%) NR 
An et al.
23
 354 Adenocarcinoma, 
144 Squamous cell, 
26 Large cell carcinoma 
Direct 
sequencing 
143 Stage I, 
72 Stage II, 
135 Stage III, 
174 Stage IV 
361 Males, 
163 Females 
8/101 (7.9%) No association 
with overall 
survival 
Suzuki et al.
36
 Adenocarcinoma Direct 
sequencing 
NR 54 Males, 
43 Females 
14 (14.4%) 3 EGFR/STK11 
double mutants 
Ding et al.
5
 Adenocarcinoma Direct 
sequencing 
75 Stage I, 
91 Stage II, 
8 Stage III, 
10 Stage IV 
NR 34 (18%) Neg. correlation 
between EGFR 
and STK11 
mutations 
Chitale et al.
37
 Adenocarcinoma Sequenom-
based 
mutation 
screens 
135 Stage I, 
27 Stage II, 
36 Stage III, 
2 Stage IV 
78 Males, 
121 Females 
28 (11%) Mutations in 
EGFR and STK11 
mutually exclusive 
NR=not reported *Sequenced 8 coding exons in 62 of 124 tumors that had loss of heterozygosity 
and identified eleven tumors (11.3% overall) with STK11 mutation.   **Only exons 1, 6, and 7. 
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 Similar to mutations in KRAS and EGFR, there is evidence to suggest ethnic/racial 
differences in STK11 mutations.  Studies in Asian populations including Japanese, Korean, and 
Chinese have reported much lower STK11 mutation rates, ranging from 3-7%  in lung 
adenocarcinoma, compared to Whites.
21,32,38,39
  This observation is similar to KRAS mutations in 
lung cancer, which frequency co-occur with STK11 mutations, where it has been noted that lung 
tumors in Western populations harbor a higher frequency of KRAS mutation (15-50%) compared 
to Asian populations (5-15%).  Asian populations have been found to express an STK11 germline 
F354L polymorphism at a higher frequency than Western populations which has been reported in 
10% of Chinese
38
 and 6% of Korean populations compared to 0.2% of a Finnish population.
40
  
This allele has not been associated with cancer predisposition, and is likely a polymorphism that 
has no effect in lung cancer, but has been previously reported to affect cell polarity maintenance 
in an AMPK-dependent manner.
41
 
 The STK11 kinase domain spans over 60% of the entire length of the protein, 
encompassing amino acids 49-309 of the total 433.  Mutations have been found throughout the 
entire gene without any well characterized hotspots.  In general, recurrent C-terminal mutations 
located outside of the kinase domain do not impair STK11 kinase activity or interfere with its 
ability to promote growth arrest.  These mutations do, however, impair STK11's regulation of the 
AMP-activated protein kinase (AMPK) cascade and cell polarity.  These mutations include 
P324L, F354L (described above to have an increased frequency in Asian popluations), and 
T367M.
41
 
 The STK11 protein is catalytically active as a heterotrimeric complex with the STE20-
related adaptor protein α (STRADα) and mouse protein-25 (MO25) and mutations have been 
found to interfere with STK11's interaction with these binding partners.  An investigation of 34 
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point mutations in STK11 revealed that 12 of these mutants failed to interact with these STRADα 
and MO25.
42
  An analysis of the mutation sites led to the discovery of two binding sites on 
opposite surfaces of MO25 required for assembly of the heterotrimeric complex.
42
 
 Variations in STK11 single nucleotide polymorphisms (SNPs) have also been linked to 
various diseases including gene variants in STK11 rs8111699 which contribute to differences in 
insulin sensitivity and metformin efficacy in hyperinsulinemic girls with androgen excess, 
leading to the conclusion that the girls with the least favorable endocrine-metabolic profile 
improved the most with metformin therapy.
43
  Another study that analyzed 772 patients with 
surgically resected colorectal adenocarcinoma for the STK11 rs741765 SNP found that the GG 
genotype was significantly associated with a worse disease free survival and overall survival.
44
 
 
DOWNSTREAM TARGETS OF STK11 
 
 As mentioned above, STK11 is catalytically active as part of a heterotrimeric complex.  
After translation, the nuclear localized STK11 binds STRADα, which shuttles the complex to the 
cytoplasm.
45
  STRADα is also responsible for stimulating STK11 catalytic activity through an 
allosteric mechanism involving binding STK11 as a pseudosubstrate.
46
  This interaction between 
STRADα/STK11 is further stabilized by MO25, which interacts with STK11's activation loop.46 
 An additional STK11 complex was discovered in which an STK11 isoform that differs in 
the C-terminal region, but not one that lacks a portion of the kinase N-terminal lobe domain, was 
found to interact with the chaperones Hsp90 and Cdc37.
47
  This non-canonical 
STK11/Hsp90/Cdc37 complex is catalytically inactive unlike the STK11/STRADα/MO25 
complex.  Dissociation of the STK11/Hsp90 complex triggers recruitment of both Hsp/Hsc70 
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and CHIP proteins which are responsible for activating STK11 degradation.  They proposed that 
these two chaperone complexes with antagonizing activities are responsible for fine tuning the 
cellular levels of STK11 protein.
47
 
 STK11 is a multi-functional kinase and has been found to be involved in a broad 
spectrum of cellular activity including metabolism, polarity, epithelial-mesenchymal transition, 
cell cycle regulation, apoptosis, and autophagy.
14
  Many of these functions are regulated through 
STK11 activation of the AMPK cascade,
48
 which is achieved through STK11 directly 
phosphorylating T172 on AMPK.
49
  Identification of an STK11 splice variant that is lacking 
S431, but is able to activate AMPK equally as effective as full-length STK11, led to the 
conclusion that phosphorylation of STK11 at S431 is not required for downstream 
phosphorylation of AMPK and other kinases, as has been previously suggested.
50
  Activation of 
AMPK and other members of the AMPK family is crucial to STK11's role as a regulator of 
cellular energy metabolism and cell polarity.
49,51
  AMPK in particular has been found to have 
great importance as it acts as a tumor suppressor, serving to promote p53 acetylation and 
subsequent apoptosis of hepatocellular carcinoma cells.
52
 
 Downstream of STK11, AMPK activation negatively regulates the mTOR pathway.  
AMPK directly phosphorylates the TSC2 tumor suppressor under conditions of energy 
starvation, which serves to down-regulate mTOR signaling,
53
 and STK11 is required for this 
repression of mTOR under low energy conditions.
54
  In addition to inhibiting mTOR through 
TSC2, AMPK also directly phosphorylates the mTOR binding partner RAPTOR which is 
required for inhibition of mTORC1 and cell cycle arrest following energy stress.
55
  These data 
together suggest a model for STK11 as a "low-energy-checkpoint tumor suppressor" in that wild 
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type STK11 acts as a sensor inducing AMPK signaling, which halts ATP-consuming processes 
in conditions of low cellular energy.
49
 
 STK11 is important in embryonic organogenesis in a tissue-dependent manner.  Some 
tissue specific examples of the effects of STK11 inhibition can be found in the pancreas where 
this loss can lead to development of precancerous lesions in an AMPK-independent manner, 
whereas inhibition of STK11 in the lung leads to a cell-autonomous branching defect, a 
phenotype that can be rescued by an AMPK activator.
56
 
 For a representation of all of the downstream targets of STK11 see Figure 4.1. 
 
STK11 AND TRANSCRIPTIONAL CONTROL 
 
 While regulation of the TSC2/mTOR pathway is clearly a major component of the 
biology of STK11 mutations, STK11 also regulates the activity of a number of transcription 
factors and transcriptional programs via poorly understood mechanisms.
57,58
  The best 
understood of these is the indirect control of CREB-regulated transcriptional cofactor (CRTC) 
phosphorylation.  CRCT proteins are excluded from the nucleus due to phosphorylation events 
downstream of AMPK and AMPK-regulated salt-inducible kinases.  In the absence of STK11, 
CRTC1 accumulates in the nucleus due to lack of phosphorylation, binds to the CREB 
transcription factor and activates transcription of CREB-regulated genes including LYPD3, 
NR4A2,
59
 and NEDD9.
60
  Two papers have recently examined the transcriptional program 
alterations associated with STK11 mutation in large lung adenocarcinoma databases
61,62
 and both 
confirmed that CREB-regulated genes are dramatically affected by STK11 mutations.  One of 
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Figure 4.1  Downstream pathways controlled by STK11 and therapeutic targets.  Inactive 
STK11 is shown in red; active STK11 in green.  Yellow 'P's represent phosphorylation events; 
orange 'U's represent ubiquitination.  Boxes in black represent downstream cellular processes; 
boxes in red represent drugs used to inhibit or activate targets. 
 
these two analyses
62
 also identified NRF2 activation and attenuation of the PI3K-AKT pathway 
as elements of STK11 mutations, suggesting the potential for targeted therapies (discussed 
below).  Interestingly, the other paper demonstrated the STK11-CRTC1 circuit regulates COX-2 
expression and its activation by glycosylation.
61
  Furthermore, this paper used the C-MAP drug 
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response database to demonstrate that the highest ranking drugs correlating positively with 
STK11-mutated gene expression signature were activators of CRTC1 including forskolin and 
numerous PGE-2 analogs.  Finally, this work demonstrated that COX-2 inhibitors specifically 
inhibited growth and motility in STK11-null cell lines and not in STK11-wild type cell lines, 
suggesting potential clinical application (discussed below). 
 
STK11 AND ADHESION 
 
 As a multifunctional tumor suppressor, STK11 has also been linked to not only intra-
cellular processes, but also the extra-cellular process of adhesion.  The N-terminal domain of 
STK11 in particular has been found to be necessary for repressing the focal adhesion kinase 
(FAK) and stabilizing focal adhesions.
63
  Loss of STK11 results in increased phosphorylation of 
FAK and enhanced adhesion to fibronectin.
63
  Adhesion of lung cancer cells to fibronectin has 
previously been found to enhance tumorigenicity and confer cell adhesion mediated drug-
resistance.
64
  Specifically, fibronectin prevents apoptosis through integrin α5β1 mediated 
activation of COX2 and inhibition of p21 gene expression, an effect not seen with other matrix 
components such as collagen type I.
65
  Fibronectin has also been found to stimulate NSCLC cell 
growth through activation of Atk, mTOR, and S6K with concurrent repression of STK11, 
AMPK, and PTEN.
66
  This fibronectin-induced cascade can by blocked using an antibody 
against integrin α5β1.66  Additionally, a novel tumor suppressor that binds to the cytoplasmic 
domain of integrin α5, Nischarin, has also been found to directly interact with STK11.67  Loss of 
Nischarin and STK11 was found to increase migration and tumor growth through increased 
phosphorylation of PAK1 and LIMK1, as well as increased Cyclin D1 levels.
67
  Another STK11 
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pathway found to negatively regulate cell adhesion involves the AMPK family member NUAK1 
which is directly phosphorylated and activated by STK11.  Inhibition of this STK11-NUAK1 
pathway has been found to  increase cell adhesion, and this pathway has been shown to be 
activated under conditions of cell detachment.
68
  
 Used as our model system for the study in Chapter 3, osteoblast differentiation was 
found to correspond with decreased phosphorylation of AMPK, a phenotype that was found to be 
inhibited by glucose restriction and metformin stimulation,
69
 so there is likely a link between the 
two pathways described.  Another cross-over between the two major tumor suppressors 
described in this dissertation is through the downstream regulation of the Rac1 pathway.  
Treatment of endothelial cells with simvastatin resulted in increased phosphorylation of STK11 
and AMPK with subsequent AMPK-mediated activation of Rac1.  Through its downstream 
pathway members STK11 has been shown to either activate or repress adhesion, adding to its 
arsenal of tumor suppressive abilities. 
 
THERPEUTIC IMPLICATIONS AND TARGETING OF STK11 MUTATIONS 
 
 At the molecular level, lung cancer is a complex and heterogeneous disease.  Molecular 
alterations in lung cancer occur at multiple levels (e.g., genetic, epigenetic, and protein 
expression) and understanding the functional significance of these alterations can yield 
improvements in diagnosis, prognosis, and treatment.
70
  New technologies in the identification of 
key and potentially targetable genetic alterations have resulted in a greater understanding of the 
molecular underpinnings of lung cancer.  Loss-of-function mutations, while more common, are 
difficult to take advantage of therapeutically, so greater understanding of the multiple 
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biochemical pathways and characterization of these molecular alterations is needed to develop 
new therapeutic treatments and targeted precision medicine.  STK11 in particular is an attractive 
target because it is the major upstream activator of the energy-sensing kinase AMPK and has 
been linked to a variety of important pathways in cancer.  Restoring STK11 activity in mutant 
tumors is predicted to both sensitize tumors to additional chemotherapies and to increase 
susceptibility of cancer cells to cell death.  Table 4.2 summarizes all of the clinical trials, pre-
clinical studies, and basic science studies that have focused on targeting STK11 deficient tumors 
using a variety of therapies. 
 A recent study sought to combine STK11 gene therapy with low-dose cisplatin-based 
chemotherapy using cationic liposomes-mediated STK11 gene, which sensitized lung cancer 
cells to cisplatin in vitro and in vivo, resulting in fewer lung metastatic nodules, and prolonged 
lifespan.
75
  They believe this sensitization occurred through up-regulation of p53 and JNK and 
down-regulation of mTOR and MMPs 2 and 9. 
 Apart from attempts to replace the down-regulated STK11 gene itself, strategies to target 
downstream members of the STK11 pathway are in various stages of development and have 
shown a range of efficacies.  Some examples of this targeting strategy include taking advantage 
of the fact that cells deficient in STK11 are known to be hypersensitive to apoptosis induced by 
energy stress
49
 as a side effect of the dysregulated AMPK pathway.  Using AICAR, an AMP 
analog capable of stimulating AMPK, it was found that AICAR treatment prevented cell death 
upon glucose depletion only in STK11 wild type cells
79
 and that multiple disparate types of 
STK11-deficient cells are sensitized to cell death by AICAR.
49
  Another means of targeting the 
metabolic dysregulation caused by STK11 loss is use of the glucose analog, 2-deoxyglucose (2-
DG), which targets tumor cells due to their increased glucose uptake.  In STK11-negative cells,  
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Table 4.2: Therapies targeting the STK11 pathway by stage of development. 
REGIMEN DISEASE STK11 STATUS N= RESULTS REFERENCE 
CLINICAL TRIALS 
Standard of 
Care 
Colorectal 
cancer 
Evaluated STK11 SNP 
rs741765 
772 
patients 
The STK11rs741765 SNP  GG genotype is 
prognostic for a worse DFS (p=0.030) and OS 
(p=0.038). 
Lee et al.
71
 
Everolimus PJS Patient 
with 
Pancreatic 
Cancer 
LOH analysis of 19p 
locus using four 
polymorphic markers 
1 
patient 
Everolimus used to achieve a partial remission in 
advanced pancreatic cancer in a PJS patient.  
Progressive disease was noted after 9 mo. of 
treatment. 
Klumpen et al.
72
 
Metformin + 
Paclitaxel / 
Carboplatin / 
Bevacizumab 
Lung 
Adeno-
carcinoma 
Secondary Outcome; 
Retrospective evaluation 
of STK11 WT vs. Mut 
Expect 
60 
patients 
Recruiting for Phase 2; Estimated completion 
April 2015. 
NCT01578551 
Sirolimus + 
Metformin 
Advanced 
Solid 
Tumors 
Secondary Outcome; 
Retrospective evaluation 
of STK11 WT vs. Mut 
Expect 
64 
patients 
Recruiting for Phase 1; Estimated completion 
July 2017. 
NCT02145559 
Metformin + 
Carbohydrate 
Restriction + 
Platinum based 
chemotherapy 
Stage IV 
NS-NSCLC 
Secondary Outcome; 
Retrospective evaluation 
of STK11 WT vs. Mut 
Expect 
60 
patients 
Recruiting for Phase 2; Estimated completion 
June 2018. 
NCT02019979 
PRE-CLINICAL STUDIES 
Docetaxel +/- 
Selumetinib 
NSCLC KRAS, p53, and STK11 
mutant mice were 
generated using 
conditional knockout 
model. 
9-28 
mice/ 
therapy 
KRAS/p53 and KRAS/STK11 mutant mice were 
resistant to docetaxel monotherapy.  Addition of 
Selumetinib restored sensitivity in KRAS/p53 
mutant tumors, but not KRAS/STK11 mutant. 
Chen et al.
73
 
BAPN NSCLC Generated KRAS; 
KRAS, STK11
L/L
; KRAS, 
p53
L/L 
mice.  
8 mice/ 
therapy 
BAPN treatment for 4 wk significantly decreased 
both tumor number and tumor volume in STK11-
deficient mice, but not STK11 WT mice. 
Gao et al.
74
 
LPs-pVAX-
STK11 + 
cisplatin 
NSCLC Added STK11 back into 
mice using gene therapy. 
7 mice/ 
therapy 
Combination of conventional ciplatin-based and 
gene therapy resulted in fewer lung metastatic 
nodules and prolonged lifespan. 
Ou et al.
75
 
Phenformin NSCLC KRAS, p53, and STK11 
mutant mice were 
generated using Cre/Lox 
system. 
5-12 
mice/ 
therapy 
KRAS/STK11 mutant NSCLC but not KRAS/p53 
mutant mice responded to phenformin as a single 
agent leading to prolonged survival. 
Shackelford et 
al.
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BEZ235 + 
Selumetinib + 
Dasatinib 
Lung 
Cancer 
KRAS/STK11 mutant 
tumors were generated in 
mice. 
3-7 
mice/ 
therapy 
KRAS/STK11 mutant lung tumors did not respond 
to Dasatinib or BEZ235/ Selumetinib, the triple 
combination Dasatinib/ BEZ235/Selumetinib 
resulted in significant tumor regression. 
Carretero et al.
77
 
BASIC SCIENCE STUDIES 
CI-1040 or 
rapamycin 
NSCLC Known STK11 status cell 
lines. 
10 cell 
lines 
KRAS/STK11 mutant NSCLC cell lines are 
sensitive to single-agent treatment with CI-1040 
or rapamycin whereas KRAS or STK11 mutant 
alone are not sensitive. 
Mahoney et al.
78
 
NS-398 or 
Niflumic Acid 
Lung 
Adeno-
carcinoma 
Known STK11 status cell 
lines; confirmed with 
Western blot. 
7 cell 
lines 
NS-398 or Niflumic acid treatment of STK11-null 
cell lines resulted in growth and cell motility 
inhibition, but not in STK11 WT cells. 
Cao et al.
61
 
AICAR / 
glucose 
depletion 
Lung 
Cancer 
Known STK11 status cell 
lines; confirmed with 
Western blot. 
4 cell 
lines/ 
STK11 
status 
AICAR treatment prevented cell death upon 
glucose depletion only in STK11 WT cells. 
Carretero et al.
79
 
2-DG NSCLC Known STK11 status cell 
lines; confirmed with 
Western blot. 
4 cell 
lines 
2-DG acted as a potent activator of apoptosis and 
caused a decrease in cell viability in STK11-null 
cells. 
Inge et al.
80
 
AICAR STK11 WT 
and null 
MEFs 
STK11-/- MEFs were 
produced by in vitro 
excision of STK11 lox 
allele. 
N/A STK11-null MEFs, but not WT or heterozygous 
controls, lost downstream phosphorylation of 
AMPK upon AICAR treatment and underwent 
rapid apoptosis. 
Shaw et al.
81
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2-DG was found to activate apoptosis in response to energetic stress.
80
  A third means of 
exploiting the inability of STK11-mutant cells to appropriately respond to metabolic stress is the 
use of therapeutic biguanides commonly used to treat diabetes, such as metformin and 
phenformin. 
 Targeting mTOR has also been shown to be effective in STK11 mutant tumors.  The 
mTOR inhibitor everolimus was used to achieve a partial remission in a patient with advanced 
pancreatic cancer induced by Peutz-Jeghers syndrome, although observable progressive disease 
occurred after nine months of mTOR inhibition likely due to selective pressure for cancer cells 
with alternative driver mutations, or a hyperactivation of an alternate pathway such as the AKT 
pathway.
72
 
 STK11 has also been found to negatively regulate lysyl oxidase (LOX) through mTOR-
HIF-1α signaling.  LOX mediates lung cancer malignancy progression by triggering extracellular 
matrix remodeling allowing for increased cell proliferation and invasion and could be a 
therapeutic target for the treatment of STK11-deficient lung cancer.  This is supported by the 
work done by Gao et al. using the LOX pharmacological inhibitor, BAPN.
18
 
 Another downstream target found to be upregulated in response to STK11-deficiency is 
the COX-2 pathway (described above).  A gene signature developed to determine STK11 
mutational status was used to search the Connectivity-MAP drug response database and returned 
results that were known or predicted activators of CRTC1, a transcription factor responsible for 
regulation of COX-2.
61
  The COX-2 inhibitors NS-398 and Niflumic acid were shown to result in 
growth and cell motility inhibition in STK11-null cell lines, but not their wild type 
counterparts.
61
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 Previously, analysis of primary and metastatic de novo lung cancers with integrated 
genomic and proteomic profiles led to the identification of gene and phosphoprotein signatures 
associated with STK11 loss and progression to invasive and metastatic lung tumors.  They found 
that SRC is activatied in STK11-deficient primary and metastatic tumors and that combined 
inhibition of SRC (using dasatinib), PI3K (using BEZ235), and MEK1/2 (using AZD6244) 
resulted in synergistic tumor regression.
77
 
 An additional method of STK11-mediated tumor suppression involves STK11 inhibition 
of the Yes-associated protein (YAP), an oncogene more commonly associated with the Hippo 
tumor suppressor pathway, which functions as a transcription factor responsible for promoting 
expression of proliferative genes.  STK11 suppresses YAP via indirect, non-canonical 
regulation,
82
 preventing YAP from inducing EMT when constitutively active.
83
  The structure of 
YAP includes several protein domains that are promising drug targets.  One such structure is the 
N-terminal domain where YAP binds the TEAD transcription factor.  This YAP-TEAD 
interaction can be inhibited by verteporfin, which has been shown to prevent YAP-induced liver 
overgrowth.
84
   Another YAP target is its WW domain which was identified in silico to be 
targetable by digitoxin,
85
 and the endohedral metallofullerenol Gd@C82(OH)22,
86
 a molecule that 
has previously been shown to have anti-neoplastic effects in tumor cells including the STK11 
mutant A549 cell line.
87
  To our knowledge, no one has compared the efficacy of these therapies 
in STK11-proficient and -deficient lung cancer cell lines. 
 Therapy decisions based solely on STK11 mutational status may not be enough, however.  
Evidence in several studies has pointed to the idea that STK11/KRAS co-mutational patients may 
represent a genetic and functionally distinct subset of NSCLC.
73,78
  STK11/KRAS mutant NSCLC 
cell lines were found to be sensitive to the MEK inhibitor CI-1040 and the mTOR inhibitor 
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rapamycin, whereas cell lines carrying single STK11 or KRAS mutations alone are not.
78
  
Similarly, phenformin was found to selectively induce apoptosis in STK11-deficient NSCLC 
cells, and in therapeutic trials using KRAS-dependent mouse models of NSCLC, tumors with 
STK11/KRAS , but not those with KRAS/TP53 mutations, responded to phenformin as a single 
agent leading to prolonged survival.
76
  An example where STK11/KRAS mutations represent a 
resistant phenotype was in a "co-clinical" trial featuring genetically engineered mouse models 
concurrently mirroring an ongoing human clinical trial in patients with KRAS-mutant lung cancer 
where it was found that concomitant loss of either p53 or STK11 impaired the response of 
KRAS-mutant tumors to docetaxel monotherapy.
73
  Addition of the MEK inhibitor selumetinib 
(AZD6244) provided substantial benefit for mice with KRAS mutations (92% overall response 
rate) and KRAS/TP53 mutations (61% overall response rate), but mice with KRAS/STK11 
mutations were more resistant (33% overall response rate).
73
 
 Currently, a series of on-going clinical trials are recruiting patients to evaluate metformin 
combined with either paclitaxel, carboplatin, or bevacizumab in lung adenocarcinoma (trial # 
NCT01578551), metformin and sirolimus in advanced solid tumors (trial # NCT02145559), and 
metformin combined with carbohydrate restriction and platinum-based chemotherapy in stage IV 
non-squamous NSCLC (trial # NCT02019979).  These trials will all evaluate STK11-mutational 
status as a secondary outcome retrospectively. 
 
CONCLUSION AND FUTURE DIRECTIONS FOR RESEARCH 
 
 Loss-of-function mutations, despite being common events in cancer, are largely ignored 
when developing and selecting therapies.  This is due to the fact that they are difficult to exploit 
84 
 
as restoring function of a gene is not something that we are currently capable of.  Despite this, 
we have a responsibility to gain a complete understanding of the biology of these tumor 
suppressors and the multitude of changes in key signaling pathways and downstream events 
caused by their loss.  With this information available, we have the best hope for developing the 
most effective therapeutic regimens possible. 
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CHAPTER FIVE: 
A Gene Expression Signature Reflecting STK11 Mutation in Lung Adenocarcinoma
XI
 
 
ABSTRACT 
 
 STK11 is a tumor-suppressor commonly mutated in lung adenocarcinoma (LuAd).  There 
are a number of agents that may selectively target the deregulated pathways in STK11 mutated 
tumors, and thus, identifying the subset of adenocarcinomas that harbor these mutations could 
have significant clinical benefit.  In the current work, we have characterized a cohort of 442 
adenocarcinoma patients with respect to STK11 mutation status and subset of this cohort using 
immunochemistry, gene expression, and western blotting.  We find that measuring STK11 
mutation status is complicated by the fact that many STK11 mutations lead to expression of a 
stable protein that is indistinguishable from wild type (WT) via immunohistochemistry.  To 
circumvent this, we used published cell line mutation and gene expression data to derive a 
signature correlating with STK11 mutation status.  This signature was validated in the cohort of 
442 lung adenocarcinomas and strongly correlates with mutation status (ROC curve AUC = 
85.29).  These data suggest that STK11 mutation status may be best assessed by measuring the 
downstream targets included in our signature. 
 
 
                                                             
XI This chapter will be submitted for publication.  See Appendix A for details. 
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INTRODUCTION 
 
 STK11 is a serine/threonine kinase also known as liver kinase β1 (LKB1).  It was first 
discovered as the gene responsible for Peutz-Jeghers syndrome,
1
 a rare heritable disease 
characterized by hamartomatous polyps of the gastrointestinal tract as well as hyper-pigmented 
macules on the lips, gums, and inner lining of the mouth.  STK11 has further been characterized 
as a potent tumor suppressor, explaining the fact that Peutz-Jeghers patients have an 
approximately 80% risk of developing cancer by age 70,
2
 especially of gastrointestinal origin. 
 The STK11 gene is located on chromosome 19p13.3 and spans 10 exons, the 10th of 
which is non-coding.  The kinase domain of the 433 amino acid protein that it encodes spans 
more than half the length of the protein encompassing amino acids 49-309.  Mutations have been 
found throughout the lengthy kinase domain with no obvious hotspots.  The STK11 protein is 
catalytically active as a heterotrimeric complex with the STE20-related adaptor protein α 
(STRADα) and mouse protein-25 (MO25).  STRADα binds STK11 in the nucleus and transports 
it to the cytoplasm where it is active,
3
 and it has been found that binding to STRADα increases 
STK11's kinase activity more than 10-fold.
4,5
  In contrast, MO25 acts as a scaffold protein and 
serves to stabilize the entire complex.  Many mutations in STK11 have been found to interfere 
with the capability to bind these partners,
6
 rendering the expressed protein inactive. 
 While the diversity of mutations discovered in the STK11 gene is large, the range of 
cancers that these mutations have been found in is comparatively small.  The only cancer type 
found to harbor a high percentage of STK11 mutations is non-small cell lung cancer (NSCLC).  
The adenocarcinoma histological subtype of NSCLC in particular has a high frequency of STK11 
mutations
7-14
 and is reported to be the third most commonly mutated gene in this cancer subtype 
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following only KRAS and TP53,
15
 pointing to its importance as a driver mutation in 
tumorigenesis.  Mutations in STK11 have been found to commonly co-occur with KRAS 
mutations, and to be mutually exclusive with EGFR mutations.
11,15,16
 
 The loss of STK11 can be particularly devastating to a cell as it plays a key role in 
maintaining glucose homeostasis.  STK11 is responsible for directly phosphorylating the AMP-
activated kinase (AMPK) at T172, as well as other members of the AMPK family of kinases 
under conditions of energy stress,
17,18
 which in turn suppress mTOR activity through 
phosphorylation of the tumor suppressor TSC2.
19,20
  Without STK11 acting as a glucose sensor, 
cells are able to continue to grow unchecked in low glucose conditions such as those commonly 
found in tumors.  In addition to its role in metabolism, STK11 has also been linked to cell 
polarity, epithelial-mesenchymal transition, cell cycle regulation, apoptosis, and autophagy.
10
 
 Kinases, such as STK11, most commonly act as oncogenes, but as a tumor suppressor 
STK11 drives tumor progression when it is lost, rendering it impossible to target directly.  
Consequently, research is focused on targeting downstream targets of STK11.  Therapies that 
reactivate AMPK, such as metformin, phenformin,
21
 and AICAR,
18,22
 and an AMP mimetic (2-
deoxyglucose)
23
 have been shown to render tumors more susceptible to chemotherapies.   
Additionally, drugs that target the downstream proteins that are up-regulated by loss of STK11 
such as mTOR inhibitors (e.g. rapamycin
24
 and everolimus
25
), cyclooxygenase 2 (COX-2) 
inhibitors (e.g. NS-398 and  Niflumic acid
26
), and lysyl oxidase inhibitors (e.g. BAPN
14
) have 
shown efficacy in STK11 mutant cells as compared to their WT counterparts.  Studies have also 
been done to evaluate the differences in chemosensitivity between tumors that harbor 
STK11/KRAS double mutations compared to STK11 alone.
27,28
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 Despite the growing body of evidence pointing to the efficacy of targeting this pathway 
in lung adenocarcinoma, patients are not currently evaluated for STK11 mutational status as part 
of standard of care treatment.  Our work seeks to develop a clinically applicable test to determine 
STK11 status by evaluating downstream markers.  With this key piece of information, clinicians 
will be able to design a more personalized therapy regimen for STK11 mutant lung 
adenocarcinoma patients. 
 
MATERIALS AND METHODS 
 
Human subjects protection 
 This study includes data from 442 lung adenocarcinoma patients that consented to the 
Moffitt Cancer Center's Total Cancer Care (TCC
TM
) protocol either at the Moffitt Cancer Center 
(179 patients) or at one of 18 TCC affiliates (263 patients) between April 2006-August 2010.  
This multi-institutional protocol has no exclusion or inclusion criteria and is open to all patients 
willing to permit access to self-reported demographics, clinical data, medical records, and tissue 
samples.  These prospectively enrolled patients are followed for life.  All work was approved by 
the University of South Florida Institutional Review Board (Appendix B). 
 
Western blotting 
 Frozen cell pellets were obtained from Fumi Kinose of the Moffitt SPORE in Lung 
Cancer Cell Core facility. All lines were authenticated by genotyping and maintained free of 
Mycoplasma.  As previously described
29, cell lysates were normalized for protein content (30 μg) 
and separated using SDS-PAGE.  Proteins were visualized using horseradish peroxidase 
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conjugated secondary antibodies and enhanced chemiluminescence (ECL; Amersham 
Biosciences, GE Life Sciences, Pittsburgh, PA, USA).  Antibodies used include an STK11  
mouse monoclonal antibody (sc-32245, Santa Cruz Biotechnology, Santa Cruz, CA, USA), a 
MO25 rabbit polyclonal antibody (M7195, Sigma), a STRAD goat polyclonal antibody (sc-
55052, Santa Cruz Biotechnology), a threonine 172 phospho-AMPKα rabbit monoclonal 
antibody (2535, Cell Signaling), an AMPKα1 rabbit polyclonal antibody (2795, Cell Signaling), 
and a β-actin mouse monoclonal antibody (A5441, Sigma). 
 
Immunohistochemistry 
 A tissue microarray (TMA) was constructed from available diagnostic paraffin blocks 
from a subset of the Moffitt patients (N = 145) of the cohort described above.  Slides from 
potential donor blocks were stained with hematoxylin-eosin and examined by a board-certified 
clinical pathologist. Appropriate blocks were released for study and representative tumor areas 
(and a subset of normal tissue areas) marked. Donor tissue cores with a diameter of 0.6 mm were 
punched and arrayed into a recipient paraffin block using a tissue arrayer (Beecher Instrument, 
Silver Spring, MD, USA). The TMA included 145 cores from primary adenocarcinomas, 58 
cores of adjacent normal lung tissue, 14 cores from non-lung tissue controls (normal and cancer) 
and 10 samples of lung cancer cell lines of known STK11 status (which were used to 
demonstrate the specificity of STK11 staining). 
 TMA slides were cut into 4 µM sections and stained with a mouse anti-STK11 
monoclonal antibody (sc-32245, Santa Cruz Biotechnology, Santa Cruz, CA, USA) at a 1:100 
dilution (staining details are available upon request). The stained TMA was reviewed by a board-
certified clinical pathologist blind to the molecular data. Normal tissue cores were examined to 
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determine staining criterion. The staining of tumor tissue was scored as either negative or 
positive with positive values ranging from +2 to +4. 
 A histology slide from a tissue micro array stained for  STK11 (sc-32245, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) was scanned using the Aperio™ (Vista, CA, USA) 
ScanScope XT with a 200x/0.8NA objective lens at a rate of 7 min per slide via Basler tri-linear-
array detection.  Each core was then segmented using the TMA block software associated with 
Spectrum to be analyzed individually. Image analysis for 227 stained cores was performed using 
an Aperio Positive Pixel Count® v9.0  algorithm with the following thresholds: [Hue Value =.1; 
Hue Width =.5; Color Saturation Threshold =0.04; IWP(High) = 220; Iwp(Low)=Ip(High) = 
175; Ip(low) =Isp(High) =100 Isp(Low) =0] to segment positive staining of various intensities. 
The algorithm was applied to the entire digital core image to determine the percentage of 
positive biomarker staining by applicable area. 
 
Statistical analysis 
 The mutational data, IHC data, clinical information, and vital status data were merged 
into a single file for subsequent statistical analyses using Stata/MP 12.1 (StataCorp LP, College 
Station, TX, USA).  Pearson's chi-squared test was used to test for differences in the distributions 
of mutational status by study population characteristics.  The Student’s t-test was used to test for 
differences in the mean IHC values by mutational status.  Survival analyses were performed 
using Cox proportional hazard regression, Kaplan-Meier survival curves, and the log-rank test. 
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 Plasmid vectors 
 The pcDNA3-FLAG-LKB1 vector was purchased from Addgene (Plasmid #8590; 
Addgene, Cambridge, MA, USA).  The STK11 gene insert was amplified from this plasmid using 
the T7 promoter and custom primer (5'-ATACTCGAGCTGCTGCTTGCAGGC-3'), excised 
using EcoRI and XhoI restriction enzymes, and cloned into those sites of the pNTAPb vector 
(Agilent Technologies, Santa Clara, CA, USA).  STK11 variants were generated by PCR using 
the following primers: D194Y forward (5'-ACCCTCAAAATCTCCTACCTGGGCGTGGC-3'), 
D194Y reverse (5'-GCCACGCCCAGGTAGGAGATTTTGAGGGT-3'), P281fs*6 forward (5'-
GACTGTGGCCCCCGCTCTCTGACCTG-3'), P281fs*6 reverse (5'-
CAGGTCAGAGAGCGGGGGCCACAGTC-3'), F354L forward (5'-
AGGACGAGGACCTCTTGGACATCGAGGATG-3'), F354L reverse (5'-
CATCCTCGATGTCCAAGAGGTCCTCGTCCT-3'). 
 
STK11 gene expression 
 Patients consented under the TCC
TM
 protocol described above were profiled for 
expression of ~60,000 distinct transcripts using a custom Affymetrix GeneChip.  Tissues were 
processed and RNA quality assessed according to the TCC
TM
 protocol.  The patient cohort was 
then de-identified, GeneChip data extracted, analyzed for hybridization quality, and processed 
using Robust Multi-Array Analysis, a model-based method of calculating expression signal.  
Microarray expression analyses were performed with CRAN, R Bioconductor using the LIMMA 
package.  The gene expression data were normalized using a pin-based Lowess-fit normalization 
algorithm.  Probesets were merged on gene symbols using a signal-to-noise-based weighted 
approach and features with more than 20% missing values were removed. 
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Transfection and immunoprecipitation 
 Cells were cultured in RMPI supplemented with 10% fetal bovine serum plus 1% 
penicillin/streptomycin. H1299 cells were cultured in 150 mm plates to approximately 70-80% 
confluency.  They were then transfected with 13 μg vector (pNTAPb), Mef2a control, or one of 
the STK11 variants, D194Y, P281fs*6, or F354L, plus 41 μg ssDNA mixed with 130 μL 
Lipofectamine-2000 in a total of 30 mL of serum-free media.  This mixture was left on the cells 
for 4 hours, then changed to complete media.  After 48 hours, cells were harvested and 
immunoprecipitated using streptavidin beads following the manufacturer's protocol (InterPlay 
Mammalian TAP System, Agilent Technologies, Santa Clara, CA, USA) stopping after the 
streptavidin elution with the exception that NETN (0.5% v/v Nonidet P-40, 20 mM Tris pH 8.0, 
50 mM NaCl, 50 mM NaF, 100 μM Na3NO4, 1 mM DTT, and  50μg/mL PMSF) was used in 
place of both the manufactuer's Lysis buffer and Streptavidin binding buffer.  The proteins were 
eluted in 30 μL 2X Laemmli buffer and the entire elution was run on the SDS-PAGE gel for 
western blotting. 
 A549 cells were cultured as above in 100 mm plates to 70-80% confluency.  They were 
then transfected with 1 μg vector (pNTAPb), WT STK11, or one of the STK11 variants, D194Y 
or F354L, additional plates received co-tranfections of WT STK11 with each of the STK11 
variants at ratios of 1 μg variant plus 1 μg WT, 1 μg variant plus 5 μg WT, or 1 μg variant plus 
10 μg variant.  All transfections were brought up to a total of 11 μg DNA using ssDNA mixed 
with 60 μL Lipofectamine-2000 in a total of 15 mL of serum-free media.  This mixture was left 
on the cells for 4 hours, then changed to complete media.  After 48 hours, cells were harvested 
and western blotted as described above. 
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Generation of STK11 mutation signature 
 Cell line gene expression and metadata was obtained from ArrayExpress
30
 accession E-
MTAB-783, supplemented with additional data from the Sanger Cell Line Project 
(http://www.broadinstitute.org/cgi-bin/cancer/datasets.cgi).  CEL files were normalized using 
IRON
31
 against the median sample.  Histology and site of origin was conformed, and several 
mis-annotated cell lines, identified as outliers through principle component analysis (PCA), were 
corrected for histology and site of origin where supported by literature (A4-Fuk, MDA-MB-435, 
NCI-H1155, NCI-H1299, NCI-H1770, NCI-H810, SK-NEP-1).  Large differences in gene 
expression were observed due to batch effect (Affy_batch in the Sanger/Broad metadata), and 
corrected for with COMBAT
32
 using a conformed combination of site of origin and histology as 
the covariate. 
 STK11 mutational status for NSCLC cell lines was curated from the literature (Luc 
Girard, personal communication) and confirmed in select cases by western blot.  Preliminary 
partial least squares discriminant analysis (PLS-DA), trained to separate mutant vs. WT, 
indicated that four WT cell lines (H292, H2170, H2342, EKVX) exhibited mutant-like gene 
expression patterns.  These four outlier cell lines were omitted from further signature generation 
analysis.  An STK11 mutation signature was generated by comparing mutant vs. WT groups 
using the following criteria for differential expression: at least three samples must have a log2 
intensity greater than 5, |fold-change| ≥ 2, and p-values from both T-test and Mann-Whitney U-
test < 0.01.  The signature was further reduced by keeping only those probesets most associated 
with the first PCA component. 
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RESULTS 
 
Expression of STK11 protein in lung adenocarcinoma 
 Forty-two cell lines with known STK11 mutational status were examined via western blot 
for STK11 protein expression (Figure 5.1A).  In all STK11 mutant cell lines, protein expression 
was absent.  In STK11 WT cell lines the protein generally appeared as a single band, however 
some cell lines blotted as a doublet or triplet, although always expressing the band for full-length 
protein of approximately 52 kD.  The exceptions were H2170, which only blotted for lower 
weight bands, and the EKVX and Calu-3 cell lines, which expressed extremely faint bands of the 
expected size. 
 In work described elsewhere, we examined a cohort of 442 adenocarcinoma patients for 
mutations in KRAS, EGFR, TP53, and STK11.  This analysis revealed that a high percentage of 
LuAd possessed mutations and copy number variations in the STK11 gene.  Many of the 
mutations identified in the previous study were of unknown significance, and thus, we sought to 
determine whether LuAd samples harboring these STK11 mutations would express STK11 
protein.  In contrast to the cell lines, blotting patient samples for STK11 yielded a wide range of 
protein expression for both WT and mutant tumors (Figure 5.1B).  The presence of WT normal 
tissue contaminating the tumor sample may account for some mutant tumors that express high 
levels of protein, but assigning STK11 mutational status by the presence or absence of a western 
blot band would be highly inaccurate. 
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Figure 5.1: STK11 protein expression in cell lines and lung adenocarcinoma tumor 
samples.  (A) Cell lines of known STK11 mutational status (denoted in parentheses) and (B) 
patients with tumors sequenced for STK11 mutational status (listed above each lane) were blotted 
for STK11 (sc-32245, Santa Cruz Biotechnology) and β-actin (A5441; Sigma).  Repeated cell 
lines were obtained from different laboratory sources. 
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IHC staining 
 STK11 staining in normal lung epithelial tissue was generally light, cytoplasmic and 
diffuse and was set to a +4 value. The staining of tumor tissue ranged from 0 to 4+ (Figure 
5.2A).  Under the staining conditions used, infiltrating lymphocytes stained a very dark brown, 
but were ignored when assigning a staining score.  Upon measuring staining using automated 
software, STK11 mutant tumors were found to have statistically significantly lower levels of 
protein compared to the WT tumors (P=0.001) (Figure 5.2B).  However, despite this trend, 
similar to the western blotting results, both STK11 WT and mutant tumors exhibited a wide range 
of staining.   
 When we dichotomized the IHC data at the overall median value, we found that tumors 
with low STK11 protein levels had improved survival compared to those with high STK11 
protein levels (Figure 5.2C), however this difference was not statistically significant (P = 0.142).  
The trend remained when we restricted this analysis to early stage tumors (data not shown), but 
the data were not statistically significant (P = 0.183). 
 
Characterization of three recurring STK11 variants 
 Three STK11 patient variants were chosen from the list of mutations that were found to 
reoccur in our previous work and previously published studies from other groups.  These 
variants, D194Y, P281fs*6, and F354L, were examined for mRNA expression levels of the 
STK11 gene (Figure 5.3A).  Due to our small sample size for each mutation, no statistically 
significant trends were found, but the D194Y mutant had the highest STK11 expression, almost 
equivalent to the average expression of WT samples.  The F354L polymorphism, which has 
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Figure 5.2:  STK11 IHC and survival probability.  (A) IHC was run on a panel of 145 lung 
adenocarcinoma tumors of known STK11 mutational status; representative cores were chosen for 
each staining level for both STK11 WT (on top) and STK11 mutant tumors (on bottom, with 
mutation listed under picture).  For the 4+ staining mutant sample, the DNA mutation occurred 
two base pairs into the intron splice site with unknown effect on the resulting protein 
(Unknown). (B) The percent positive pixels staining for STK11 for each core was determined 
using the Aperio Positive Pixel Count® algorithm, stratified by mutational status of the core, and 
separated into quartiles. (C) Survival probability for both STK11 mutant and WT tumors was 
determined using a Kaplan Meier curve.  No significant difference was noted. 
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previously been found in Asian populations at approximately 10% frequency,
33
 has been called a 
polymorphism in lung cancer, having no effect on STK11 catalytic activity.  We decided to 
explore it further, however, because it has also been reported to affect cell polarity through an 
AMPK-dependent mechanism.
34
  This F354L variant expressed STK11 at levels just greater than 
the average mutant sample still falling within the range of the second quartile of WT STK11 
expression.  The P281fs*6 mutation resulted in the lowest STK11 expression of the three variants 
examined, with expression levels just above the first quartile of all STK11 mutant samples. 
 We next sought to determine if the three variants could bind the other members of the 
catalytically active STK11 trimeric complex, MO25 and STRAD.  This was done by transfecting 
WT STK11 as well as each of the three variants into H1299 cells which contain an intact STK11 
pathway.  The exogenous STK11 was immunoprecipitated using streptavidin beads and blotted 
for its binding partners.  The WT STK11, as well as the D194Y and F354L variants were able to 
bind MO25 and STRAD (Figure 5.3B).  The P281fs*6 mutant, however, showed no binding to 
either MO25 or STRAD, and was thus dropped from further characterization as STK11 is 
catalytically inactive without the other members of the complex. 
 Finally, we examined the remaining two variants for dominant negative activity by 
transfecting the variant alone, and variant plus WT in 1:1, 1:5, and 1:10 ratios, into A549 cells 
which lack endogenous STK11 and looking for downstream phosphorylation of AMPK.  The 
D194Y mutant was able to suppress activation of AMPK by the WT STK11 at all ratios 
examined, keeping AMPK phosphorylation levels close to ambient background, as measured 
when transfecting in the empty vector alone (Figure 5.3C) marking it as a dominant negative 
form of the STK11 protein.  This D194Y mutation has previously been noted in Peutz-Jeghers 
syndrome, NSCLC, and has been found to be a residue involved in Mg
2+
 binding and catalysis,  
110 
 
 
Figure 5.3: Characterization of three recurring STK11 variants.  (A) The panel of 442 lung 
adenocarcinomas were evaluated via microarray for gene expression of STK11, stratified by 
mutational status, and separated into quartiles.  STK11 expression for the three variants that were 
chosen, D194Y (N=3), P281fs*6 (N=4), and F354L (N=4), were averaged and plotted against 
the STK11 mutant quartiles. (B) Empty vector, a vector control, WT STK11, and each of the 
three variants were transfected into H1299 cells, immunoprecipitated using streptavidin beads, 
and blotted for binding to MO25 (M7195, Sigma), and STRAD (sc-5502, Santa Cruz). (C) 
Empty vector, WT STK11, and each of the three variants alone, and variant plus WT in 1:1 
(denoted with +), 1:5 (denoted with ++), and 1:10 (denoted with +++) ratios, were transfected 
into A549 cells and blotted for AMPK phosphorylated at T172 (p-AMPK; 2535, Cell Signaling), 
total AMPK (AMPKα1; 2795, Cell Signaling) and β-actin (A5441; Sigma). 
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so despite being expressed, the lack of downstream activation of the pathway correlates to the 
importance of this residue.
35-37
  Conversely, the F354L variant phosphorylated AMPK in the 
presence, or absence, of WT protein, and is likely a polymophism that does not have any real 
effect on the protein's catalytic activity. 
 
An STK11 gene expression signature derived from a panel of cell lines of known STK11 
mutational status 
 Forty-eight cell lines (Table A1) with defined STK11 status and gene expression data 
from the Connectivity Map (CMAP) of the Broad Institute (http://www.broadinstitute.org/) were 
used to define a gene signature correlating with STK11 mutation status.  The genes used to make 
the signature are listed in Table A2.  Figure 5.4A shows the first and second principle 
components of the signature for all cell lines. The first principle component separates the cell 
lines into WT and mutant, except for five lines indicated in yellow (H292, H2170, H2342, and 
two sources of EKVX).  In the Western blot analysis of these cell lines (Figure 5.1A), H292 
appears as a triplet, H2170 is missing the wild type band but has three lower molecular weight 
bands, H2342 has a band at the expected wild type size, and EKVX has a faint band of the 
expected wild type size.  All of these lines were excluded from further analysis.  NR4A2 is the 
strongest gene in the signature and has previously been found to be downstream of STK11
38,39
 
with potential to be used as a marker of STK11 mutation. 
 
The STK11 gene signature can be used to classify human tumors 
 We next assessed the STK11 gene signature using the panel of 442 lung adenocarcinoma 
for which the mutation status and copy number (data not shown) of STK11 was determined.  
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Figure 5.4: STK11 gene expression signature.  (A) First principal component analysis of an 
STK11 gene expression signature was developed in cell lines; units are arbitrary. (B) First 
principal component analysis of this gene expression signature validation in the cohort of 442 
patients; units are arbitrary. (C) The performance of the STK11 gene signature, developed in cell 
lines was tested using a receiver operating characteristic (ROC) curve to determine how well it 
correlated with known STK11 mutational status samples in the 442 patient cohort. 
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Figure 5.4B demonstrates that the signature derived in cell lines is also present in in vivo tumors.  
There are exceptions on both sides.  Our gene expression signature was also found to highly 
correlate with STK11 mutational status as seen in the ROC curve (AUC = 85.29) (Figure 5.4C). 
 
CONCLUSIONS 
 
 We have examined STK11 DNA mutational status and the resulting levels of both STK11 
mRNA and protein and found that while a mutation in the DNA sequence results in an inactive 
protein, it does not necessarily abrogate expression of either mRNA or protein.  Conversely, WT 
STK11 tumors have been shown to have a wide range of expression of both STK11 mRNA and 
protein.  While DNA sequencing is a viable option to determine a patient's STK11 mutational 
status, it is a cumbersome process involving the sequencing of nine individual exons.  The 
majority of mutations revealed through sequencing have not been characterized for downstream 
activity, so even after sequencing it is unclear whether the STK11 downstream pathway has 
indeed been inactivated.  In order to solve this problem, we have developed an STK11 gene 
expression signature comprising genes both related to and downstream of STK11 and the STK11 
pathway.  This signature can separate both STK11 WT and mutant cell lines and patient samples. 
 With the resulting STK11 mutational status in hand, a clinician will eventually be able to 
offer patients a more personalized treatment regimen of one of the many drugs in development to 
target the altered STK11 pathway.  In our own work we have found that our STK11 signature 
correlates with drug sensitivity to COX-2 inhibitors (data not shown) and have published a study 
looking at the effects of these COX-2 inhibitors in both STK11 WT and mutant cell lines.
26
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 With the American Cancer Society estimating over 224,000 new incidences of lung 
cancer in the U.S. in 2014 (Cancer Facts and Figures), and approximately 35-40% of these lung 
cancers being classified as adenocarcinoma, there is a huge demand for a test like ours and we 
look forward to helping these patients receive the most efficacious treatment possible. 
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CHAPTER SIX: 
Conclusions and Future Directions for Research 
 
TARGETING TUMOR SUPPRESSORS 
 
 Current strategies to treat cancer rely heavily on reducing the activity of overactive 
oncogenes, however this approach largely ignores tumor suppressors, as restoring function of 
these sentinel proteins is a more difficult task.  There are several strategies that seek to restore 
the activity of tumor suppressors, most commonly through targeting downstream pathway 
members which are amplified upon loss of the tumor suppressor.  Other targeting strategies 
include directly restoring normal gene expression through gene therapy.  This involves 
packaging wild type tumor suppressor DNA in viral hosts and using them to infect tumor tissues, 
or less commonly by using either DNA plasmids directly, or packaging these plasmids in 
liposomes or polymers.
1
  For tumor suppressors that are being suppressed by DNA methylation 
or histone deacetylation, activity may be restored through the use of DNA methyltransferase 
inhibitors (e.g. Decitabine) or histone deacetylase inhibitors (e.g. Vorinostat and Romideosin).  It 
has also been suggested that bypassing restoration of tumor suppressor function may be a viable 
option through the use of microRNAs.  Similar to proteins with oncogenic or tumor suppressive 
functions, specific microRNAs may fulfill these same roles and restoring faulty microRNAs may 
be an easier task with more far-reaching effects as individual microRNAs have been shown to 
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regulate hundreds of genes.  A riskier strategy involves actually targeting normally functioning 
tumor suppressors that are redundant activators of pathways no longer activated by the tumor 
suppressor lost in cancer cells.  The idea behind this strategy is that targeting a redundant protein 
in healthy tissues will be compensated for by the normally functioning tumor suppressor.  In 
tumor tissues, however, where the tumor suppressor is already lost, targeting the redundant 
protein will abrogate all activation of the essential pathway leading to cancer cell death.  Proof-
of-concept studies using this strategy targeted the genes ENO1 and ENO2 in glioblastoma.
2
  
There is still a lot of work that needs to be done to develop strategies to restore activity of each 
of the major tumor suppressor, but the concepts described above may prove effective in the 
future. 
 The two major tumor suppressors discussed in this dissertation can currently be targeted 
in cancer using several of the strategies mentioned above.  Specifically, the pRb pathway can be 
targeted by inhibiting downstream pathway members that are up-regulated upon loss of pRb 
using CDK inhibitors and E2F inhibitors.  Restoration of pRb activity is also being attempted by 
re-expressing the CDKN family member, p16, which is itself a tumor suppressor, using 
adenovirus-mediated gene therapy.
3
  Similarly, adenovirus-mediated gene therapy has been used 
to try to restore the STK11 gene, while the downstream pathway is being targeted by inhibiting 
proteins that are up-regulated upon loss of STK11 using mTOR inhibitors, COX-2 inhibitors, 
and LOX inhibitors.  Reactivation of the downstream pathway is being achieved using AMPK 
activators such as metformin, phenformin, and AICAR.  Understanding the molecular biology of 
these two major tumor suppressors is vital in our quest to develop additional strategies to 
specifically restore the function of these critical proteins. 
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CONCLUSIONS FROM THE WORK PRESENTED IN THIS DISSERTATION 
 
 Chapters 2 and 3 explored the major tumor suppressor, pRb.  This protein, which is lost 
in the majority of human cancers has been widely characterized as a cell cycle suppressor, but 
newly emerging work is also linking it to the process of cell-to-cell and cell-to-extracellular 
matrix adhesion.  The status of current work outlining the mechanisms and pathways by which 
pRb controls these adhesive properties is leading toward a greater understanding of this protein 
and paving the way for future means of exploiting its loss therapeutically.  Specifically, pRb was 
found to up-regulate expression of the adhesion protein, integrin α10.  In addition to changes in 
this integrin subunit, three others, integrins α7, α8, and β4 were also found to undergo changes in 
expression in tumor tissue compared to normal tissue in multiple common solid tumor types. 
 Chapter 4 and 5 discussed the major tumor suppressor STK11 with a focus on its 
molecular biology and therapeutic implications.  Currently there are no approved therapies 
specifically for patients with STK11 loss-of-function mutations, however a variety of strategies 
are being explored at the basic science, pre-clinical, and clinical trial levels.  These therapies 
seek to restore normal pathway activity in patients affected by loss-of-function STK11 mutations.  
Once therapies are approved, the next question will be how to identify patients that will benefit 
from these therapies, as patients are not currently clinically evaluated for their STK11 mutational 
status.  Our work has identified a gene signature made up of downstream pathway members and 
other genes affected by STK11 loss-of-function mutations.  This signature can identify patients 
with an aberrant STK11 pathway with the hope that these patients will soon be eligible to receive 
therapies specifically targeting their personal mutational spectrum. 
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FUTURE WORK ON INTEGRINS 
 
 The majority of our experimental work on integrins was focused on the transcriptional 
control of integrin α10 with bioinformatic work that led to the identification of an 'integrin 
switch' in multiple solid tumors.  Further work would be necessary to fully characterize the four 
integrins involved and confirm the bioinformatically identified 'switch.'  Real-time PCR could be 
used to quantify differences in transcriptional levels of integrin mRNA, while western blotting or 
immunofluorecence could be used to visualize changes in the levels of these proteins in the 
predicted solid tumor types.  Changes in the mRNA or protein levels of these four integrins 
could be further analyzed for their expected correlation to the proclivity of tumors to metastasize 
with high levels of the three protective integrins, α7, α8, and α10 indicating a good prognosis, 
and high levels of the detrimental integrin, β4, indicating a poor prognosis.  This four integrin 
signature could potentially be developed into a prognostic patient biomarker test.  Increased 
levels of integrin β4 could also be targeted therapeutically as the extracellular domains of 
integrins could be ideal substrates for small molecule inhibitors, targeted antibodies, or binding-
domain peptide mimetics. 
 Another potential future direction for the integrin project involves the continued 
elucidation of pRb's control of several other adhesion proteins.  Our preliminary work identified 
multiple integrins and cadherins that appeared to be regulated by pRb including upregulation of 
cadherins 1, 11, and 26 as well as integrins α1, α8, and β3 and downregulation of cadherins 2 and 
6, as well as integrins α6, β7, and βL1, relationships all confirmed by real-time PCR in pRb-
proficient and -deficient SAOS-2 osteosarcoma cells.  These relationships could all be further 
explored for the mechanism linking them to pRb. 
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 Ultimately, our work serves to strengthen the link between pRb and adhesion.  While 
there are drugs that target each of these pathways individually, developing therapeutic regimens 
that combine these drugs, or eventually developing targeted therapies to restore adhesion 
dysregulated by the loss of pRb may be an extremely beneficial strategy for treating the greater 
than 50% of human tumors that are characterized by loss of pRb. 
 
FUTURE WORK ON STK11 
 
 Additional work on STK11 is currently underway with our gene expression signature 
being transformed into codesets compatible with the Nanostring platform.  This platform is an 
amplification-free method for detecting small amounts of mRNA from patient samples through 
hybridization to fluorescently bar-coded probes for predetermined target genes.  These results 
will be compared with our previous microarray-based signature to narrow down our gene list to 
those that are similarly modified on both platforms helping to create the smallest, most robust 
signature possible.  This newly refined signature will also be tested in outside datasets 
independent of the 442 patients from the SPORE cohort.  These datasets, including the TCGA, 
may help refine the gene list to narrow it down to the smallest number of maximally informative 
genes.  With the final gene list defined, the ultimate goal for this signature is to develop it into a 
patient diagnostic test used to clinically identify the mutational status of STK11 in order for 
patients to receive treatment specific to their unique mutational landscape.  With multiple clinical 
trials currently underway investigating the response of STK11 mutant and wild type patients to a 
variety of therapies, it is our hope that evaluating the status of this gene will be informative for 
future standard of care therapy options. 
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 This gene expression signature was also tested against CMAP drug-response signatures 
resulting in a series of hits.  These drugs were largely related to prostaglandins and the COX-2 
pathway.  Some initial work was done on testing a few of these drugs in STK11-proficient and -
deficient cell lines.  Follow-up studies on more of the drugs, including the subset that are not 
COX-2 inhibitors, may yield viable treatment options not yet explored for STK11 mutant 
patients.  Lung adenocarcinoma is a very deadly disease and currently no targeted therapies are 
available for patients with STK11 mutations.  Our work will continue to focus on identifying new 
therapeutic strategies and the patients that will benefit most from them. 
 
 
THE FUTURE OF CANCER TREATMENT 
 
 In the words of Hippocrates, "It is more important to know what sort of person has a 
disease than to know what sort of disease a person has."  While this concept has been around for 
several millennia, it is truly the future of cancer treatment.  With the widespread use of 
oncogenomics to analyze each patient's individual mutation spectrum and develop a unique 
treatment regimen, 'personalized medicine' is truly becoming a reality.  With a strong foundation 
of basic science being translated into the clinic, it is our hope that each piece of information we 
uncover about the inner workings of these devastating cancers will result in more effective 
treatments in the future. 
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protocol. Please note that your approval for this study will expire on 02/01/2012. 
 
Approved Items: 
Protocol Document(s): 
 
Protocol (version 2, 01/11/2011) 1/18/2011 3:05 PM 0.01 
 
It was the determination of the IRB that your study qualified for expedited review which includes 
activities that (1) present no more than minimal risk to human subjects, and (2) involve only procedures 
listed in one or more of the categories outlined below. The IRB may review research through the 
expedited review procedure authorized by 45CFR46.110 and 21 CFR 56.110. The research proposed in 
this study is categorized under the following expedited review category: 
 
(5) Research involving materials (data, documents, records, or specimens) that have been collected, or 
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APPENDIX C: Cell Lines Used to Derive the STK11 Signature 
Table A1: Cell lines used to derive the STK11 signature 
Cell Line NSCLC Subtype STK11 Status 
H1437** Adenocarcinoma E98-G155del 
H2126 Adenocarcinoma Y156-G268del 
H1993 Adenocarcinoma E199* 
H1395* Adenocarcinoma E57Kfs*7 
H1355 Adenocarcinoma K48fs*3 
H460 Large Cell Q37* 
A549 Carcinoma, unspecified Q37* 
H1573 Adenocarcinoma S216F 
H2030 Adenocarcinoma E317* 
EKVX* Adenocarcinoma WT 
H1755 Adenocarcinoma P281fs*6 
H292 Mucoepidermoid WT 
H23 Adenocarcinoma W332* 
H1666 Adenocarcinoma A200fs*87 
H838 Adenocarcinoma T212fs*75 
A427 Carcinoma, unspecified Large N-term deletion 
H2342 Adenocarcinoma WT 
H157 Squamous Cell Carcinoma E98-G155del 
H2170 Squamous Cell Carcinoma WT 
H520 Squamous Cell Carcinoma WT 
H1563 Adenocarcinoma WT 
H2405 Adenocarcinoma WT 
H1650 Adenocarcinoma WT 
Calu-3 Adenocarcinoma WT 
H441 Adenocarcinoma WT 
H2009 Adenocarcinoma WT 
H1651 Adenocarcinoma WT 
H522 Adenocarcinoma WT 
H596 Adenocarcinoma WT 
H661 Large Cell Carcinoma WT 
H1703 Squamous Cell Carcinoma WT 
H1793 Adenocarcinoma WT 
H1693 Adenocarcinoma WT 
H358 Bronchioalveolar WT 
H1792 Adenocarcinoma WT 
H2228 Adenocarcinoma WT 
H1838 Adenocarcinoma WT 
Calu-6 Adenocarcinoma WT 
H650 Bronchioalveolar WT 
H2087 Adenocarcinoma WT 
H1975 Adenocarcinoma WT 
Calu-1 Epidermoid carcinoma WT 
H2347 Adenocarcinoma WT 
H2291 Adenocarcinoma WT 
HOP-92 Large Cell Carcinoma WT 
SK-LU-1 Adenocarcinoma WT 
HOP-62 Adenocarcinoma WT 
H226 Squamous Cell Carcinoma WT 
NSCLC subtype from ATCC; STK11 status from the Connectivity Map (CMAP) of the Broad 
Institute (http://www.broadinstitute.org/).  Cell lines are listed in the ranked order of their first 
principle component with most 'mutant-like' listed first and most 'WT-like' listed last.  Single 
asterisks indicate cell lines that had two subtypes that were used to derive the signature.  Double 
asterisks indicate cell line that had three subtypes that were used to derive the signature.  
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APPENDIX D: Genes in the STK11 Signature 
Table A2: Genes in the STK11 signature 
ABCA1 LHFP 
ADRB2 LYST* 
ALDH3B1 MALT1 
APBB2 MAP7* 
APOBEC3G MECOM 
ARHGEF3 MERTK 
ATF7IP MFGE8 
AVPI1 MUC5B 
BCAT1* MX2 
C21orf96 MYLK 
CASP9 NPC2 
CDKN1C NR4A1 
CEP170 NR4A2* 
CFI NR4A3 
CLIC2 PDE4B* 
CLIP4 PDE4D* 
CPS1* PDLIM4 
CSGALNACT1 PDP1 
CTSB PELI1 
CYP1B1* PLSCR1 
DENND4B PRKAA2 
DLG1 PSIP1 
DPM3 PTGES* 
DPYD PTP4A1* 
DPYSL3 SEC14L1* 
EDNRA SEC14L1 LOC729799 
EFNB3 SETD6 
EPB41L2 SH2B3 
EPHB2* SHANK2* 
FGA* SIK1 
FGB SLFN12 
FGG SLIT2 
FLJ20935 fis, clone ADSE01534 SMAD2* 
FOXN3 SPATS2L 
Glutaminase isoform C SPDEF 
GRAMD1B STAC 
GRK5 TACC2* 
GUCY1B3 TBC1D30 
HAL* TFF1 
HEG1 TRIM2 
HERC6 TRIO* 
HGD TYMP* 
IFI27 UBE2L6 
IFI44 ZCCHC24 
IFI44L ZFP36L1* 
IFIT1 ZNF177 ZNF559-ZNF177 
IGF2BP2 ZNF415 
KCTD14 NDUFC2-KCTD14 ZNF43* 
KIAA1598 ZNF85 
LGSN ZNF93* 
Genes are listed alphabetically.  Asterisks indicate that multiple probesets were used for that 
gene. 
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